

Transforming the future of Cancer Care through the View of Biodesign-inspired Innovations and Upgraded Clinical Applications

Sergey Suchkov^{1-13*}, Michael J. Duffy^{15,16}, Hiroyuki Abe^{7,17}, R. Holland Cheng¹⁴

¹N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Moscow, Russia

²InMedStar, Russia

³China Hong Kong Innovation International Business Association, Hong Kong

⁴Russian Academy of Natural Sciences, Moscow, Russia

⁵New York Academy of Sciences, USA

⁶EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU

⁷ISPM (International Society for Personalized Medicine), Tokyo, Japan

⁸PMC (Personalized Medicine Coalition), Washington, DC, USA

⁹AMEE (Association for Medical Education in Europe), Centre for Medical Education, Dundee, Scotland

¹⁰ACS (American Chemical Society), Washington, DC, USA

¹¹AHA (American Heart Association), Dallas, TX, USA

¹²ARVO (The Association in Research in Vision & Ophthalmology), Rockville, MD, USA

¹³ISER (International Society for Eye Research), Anchorage, AK, USA

¹⁴Dept of Molecular and Cellular Biology, College of Biological Sciences, University of California Davis (UC Davis), Davis, CA, USA

¹⁵UCD Clinical Research Centre, St Vincent's University Hospital, Dublin 4, Ireland

¹⁶UCD School of Medicine and Medical Science, University College Dublin, Dublin 4, Ireland

¹⁷Abe Cancer Clinic, Tokyo, Japan

*Correspondence Author:

Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Moscow, Russia
2InMedStar, Russia.

Citation: Sergey Suchkov, Michael J. Duffy, Hiroyuki Abe, et al. Transforming the future of Cancer Care through the View of Biodesign-inspired Innovations and Upgraded Clinical Applications. *J Med Clin Sci Res.* 2026, 1(1), 01-26.

Received Date: 12 July 2026

Accepted Date: 18 July 2026

Published Date: 20 July 2026

Annotation

With advancements in technology, an improved understanding of cancer biology, and in-novative treatment modalities, oncology is evolving at an unprecedented pace towards a new ERA in clinical cancer practice.

There have been breakthroughs in numerous areas of design-driven transdisciplinary re-search, including genomics and related OMICS subareas, cancer stem cell biology, and systems biology and translational bioinformatics. This has led to the availability of many more diagnostic and predictive tests and targeted treatments for cancer and pre-cancer conditions, and has moved the practice of oncology toward healthcare services of the next-step generation, i.e., **Personalized & Precision Medicine (PPM) as applicable to daily oncology practice called Personalized & Precision Oncology (PPO)**.

Aimed at addressing inequities in access to prevention, diagnosis and treatment of can-cers, PPM model will develop a multi-disciplinary networking approach to identify the barriers to access, propose an action plan, and utilize networks to improve the quality of care for cancer patients and pre-cancer persons-at-risk as well.

Transforming cancer outcomes requires a comprehensive suite of tests and treatments for all patients before, during, and after a diagnosis. From a practical standpoint, we need to think of the future of PPM-guided cancer care as a war on three main fronts:

- (i) pre-cancer prevention,
- (ii) cancer care effective treatment, and
- (iii) post-cancer care and rehabilitation.

Pre-cancer prevention can now also mean mitigating individualized genetic risk factors and reducing the chances of developing an actual cancer with the full-scale clinical manifestations. For instance, women with mutations in the tumor suppressor genes BRCA1 and BRCA2 genes, who are susceptible to breast and ovarian cancer, could receive a preventive-prophylactic therapy called a biological modifier that can reduce the chronic inflammation or metabolic syndrome that causes cancer to grow.

Cancer care itself will become increasingly diagnostic, predictive and prognostic – the oncologist will have to understand the initial genetic makeup of the tumor, and better stratify patients based on their genetics to optimize personalized treatment decisions.

The biggest challenge in post-cancer care, also known as follow-up care, is to predict and prevent subsequent relapses, including forming metastatic regional nodes.

The ability to get better at measuring residual disease, thanks to next generation sequencing (NGS), mass-spectrometry and immunochemistry-related technologies, cytometry assay, and liquid biopsies, globally, and particularly. Detecting and characterizing residual cancer could help us tailor additional therapies to keep the disease suppressed. With new technological options, the practitioner could quantify the immune status of a cancer patient and pre-cancer person-at-risk, which largely determines the risk of recurrence or cancer induction, respectively. This will help to choose evidence-based multi-targeted immune therapies that could help prevent recurrences or suppress the transformation of pre-cancer condition into clinical cancer.

Follow-up care means more than monitoring for disease recurrence. Evidence is growing that wellness and lifestyle changes, especially changes in exercise, personalized cancer nutrition and precision foodomics, and overall well-being, support survival and recovery, and also reduce recurrences. In the future, stratifying patients pre-early on and delivering targeted, effective pre-ventive, prophylactic and therapeutic treatments will lead to the best possible outcomes. This will lower hospitalization rates for cancer patients and outpatient consultation visits for pre-cancer persons-at-risk, lower healthcare costs to society, and save lives.

PPO is emerging as a complementary approach that aims to bridge the gap between genotype and phenotype by modelling individual tumors in vitro. Those patient- and pre-cancer person-at-risk-derived ex vivo models largely preserve several tumor characteristics that are not captured by genomics approaches, and enable the functional dissection of tumor vulnerabilities in a PPM-guided manner. Those developments have opened exciting new avenues for PPO-guided clinical cancer practice, with the potential for successful applications in contexts in which genomic data alone are not informative.

The concept of PPM and PPM-guided oncology focuses

on tailoring treatment based on individual patient characteristics, including genetic profiles and specific tumor features. Meanwhile, the integration of traditional cancer treatments with complementary therapies is gaining attention. Practices such as food design-driven personalized nutrition, and mind-body interventions are being studied for their potential to enhance treatment outcomes and improve quality of life.

The integration of biomarkers into clinical practice is a key component of PPO. So to re-ally understand PPO, we would have to understand the various fields of Biodesign-driven translational applications that provide the tools to exploit and practice PPO, and genomics- and phenomics-related tools, in particular! PPM and PPO along with the “OMICS-guided” diagnostic, predictive, prognostic and therapeutic manipulations are expressions used for this paradigm shift often interchangeably [17-31,167].

Multi-OMICS technologies provide profound insights into cancer biology and PPO-guided clinical cancer practice. A fundamental computational approach for analyzing multi-OMICS data is differential analysis, which identifies molecular distinctions between cancerous and normal tissues. Such approaches offer a more nuanced understanding of cancer biology and are instrumental in pinpointing PPO-guided therapeutic strategies [193].

Genomic information, in particular, is increasingly being incorporated into clinical care. Genomic profiling can provide clinically relevant information regarding somatic point mutations, copy number alterations, translocations, and gene fusions. Continued advancements in precision genomics promise to further expand the application of genomics-enabled medicine to a broader spectrum of patients and persons-at-risk, in particular [165].

The uptake of PPM, while advancing in cancer care, has faced several adoption challenges, including education, policy, and practical factors. For instance, personalized cancer treatment in particular stands to highly benefit from PPO-driven therapies, since extensive variability between tumors presents a need to target each case in a personalized manner. At this point, personalized cancer therapy is considered to be a treatment strategy centered on the ability to predict which patients are more likely to respond to specific cancer therapies. This approach is founded upon the idea that cancer biomarkers are associated with patient prognosis and tumor response to therapy. And personalized tumor molecular profiles (tumor biomarkers can be OMICS-profiles that predict therapy response) tumor disease site and other characteristics are then potentially used for determining optimum individualized therapy options [18-31, 161,167, 197].

Improved cancer patient (or pre-cancer person-at-risk) outcomes with the application of the biomarker tests must consider not only increased survival or quality of life, but also improved clinical decision support (CDS) & making leading

to the avoidance of unnecessary therapy or toxicity. So, bioinformatics, artificial intelligence (AI), machine learning (ML) and biostatistics will be crucial in translating those Big Data into useful clinical and pre-clinical applications, leading to improved diagnosis, prediction, prognostication and treatment [32-37,166].

The EDITORIAL describes along modern modes and technologies of diagnostics, translational cancer therapeutics and the way forward from clinical and molecular diagnosis to treatment. Also the Review concerns the role of bioinformatics and biostatistics, considering the Big Data analysis serving PPM and PPO approaches.


Facilitating the transformation toward PPM that will improve patient outcomes in the oncology setting requires a coordinated effort among policymakers, cancer agencies, health systems, and industry. To implement PPM effectively in cancer practice requires an informatics solution beyond the legacy electronic medical record platforms currently available to clinical teams.

Therefore, the proposed EDITORIAL demonstrates the

successful evidence for the use of PPM-driven resources in the treatment of cancer and its future clinical perspectives as PPO-driven trends. The latter fills the gaps in cancer biology and oncology with its up-to-date content and well-designed sections. It will serve as a valuable resource for biodesigners, general practitioners, oncologists, medical students, and interdisciplinary researchers. And the concept of PPM and PPO as its branch appear to hold promising results, having potential benefits for the effectiveness of care, new disease taxonomy, and population healthcare as a whole.

1. The Introductory

Contemporary views of human disease (including cancer) and thus modern medicine, clinical oncology and global healthcare are based on simple correlation between clinical syndromes, pathological analysis and data rooted in the latest research and applications. In this context, the link that might exert reliable control over morbidity, mortality and disabling rates and to thus improve the healthcare services and to significantly optimize the efficacy of treatment for those who had fallen ill (patients) and for persons-at-risk is **Personalized & Precision Medicine (PPM)** (Figure 1).



PPM uses a patient's genetic profile to guide decisions about disease prevention, diagnosis, and treatment. That is GENES, **GENOME CLUSTERS and GENOME LANDSCAPES** are really the core of PPM being assessed and analyzed by diagnostic, predictive and prognostic analytics tools, on one hand and presented to the practitioners, on the other one.

PPM as being the Grand Challenge to forecast, to predict and to prevent is rooted in a big and a new science generated by the achievements of:

♦ *systems biology* [39-47] (Fig. 2A):




Figure 2A Systems Biology in theory

Systems biology is a comprehensive quantitative analysis of the manner in which all the components of a biological system interact functionally over time. Systems biology is a field of research that focuses on understanding whole biological systems, such as protein complexes, metabolic pathways, or gene regulatory networks, and it attempts to understand cells, tissues, and organisms and how they behave and function from a systems perspective. Systems biology is an integrative discipline connecting the molecular components within a single biological scale and also among different scales (e.g. cells, tissues and organ systems) to physiological functions and organismal phenotypes through quantitative reasoning, computational models and high-throughput experimental technologies. In other words, systems biology is a computational and mathematical analysis and modeling of complex biological systems, and a systemic view of biological issues means that the function of no organ is independent of the other so that the behavior of all components will affect the behavior of the whole system.

The masses of data generated by high-throughput technologies are challenging to manage, visualize, and convert to the knowledge required to improve patient (including cancer patient and pre-cancer person-at-risk) outcomes. Systems biology integrates engineering, physics, and mathematical approaches with biologic and medical insights in an iterative process to visualize the interconnected events within a cell that determine how inputs from the environment and the network rewiring that occurs due to the genomic aberrations acquired by patient tumors determines cellular behavior and patient outcomes. A cross-disciplinary systems biology effort will be necessary to convert the information contained in multidimensional data sets into useful specific (including cancer) biomarkers that can classify patient tumors by prognosis and response to therapeutic modalities and to identify the drivers of tumor behavior that are optimal targets for cancer therapy. An understanding of the effects of targeted therapeutics on signaling networks and homeostatic regulatory loops will be necessary to prevent inadvertent effects as well as to develop rational combinatorial therapies. Systems biology approaches identifying molecular drivers and biomarkers will lead to the implementation of smaller, shorter, cheaper, and individualized clinical trials that will increase the success rate and hasten the implementation of effective therapies into the clinical armamentarium.

From: 39-44

♦ *integrative medicine* (Fig. 2B):




Figure 2B Integrative medicine

Integrative medicine, as defined by the American Board of Integrative Medicine® (ABOIM) and the Consortium of Academic Health Centers for Integrative Medicine, is the practice of medicine that reaffirms the importance of the relationship between practitioner and patient, focuses on the whole person, is informed by evidence, and makes use of all appropriate therapeutic approaches, healthcare professionals, and disciplines to achieve optimal health and healing. Integrative health and medicine has emerged as a movement that focuses on the whole person, considering the individual in its physical, psychological, spiritual, social and environmental context, and is inclusive of all professions and practices that use this approach. Integrative health and medicine stands for an evidence-informed integration of conventional biomedicine with traditional and complementary medicine (T&CM). All appropriate therapeutic approaches and healthcare disciplines are used to achieve optimal health and healing, while recognizing and respecting the unique contribution from many medical systems."

From: 52,53

♦ *biodesign-driven translational research & applications* (Fig. 2C,D):




Figure 2C,D Modern approaches towards biomedical translation: predicting translational progress in biomedical research & applications

The impact of systems biology & fundamental biological discoveries is not reaching the clinical setting at a pace that was expected. In order to bridge this gap, the focus of biomedical researchers has shifted from OMICS-driven discoveries to "translating" only clinically relevant biological information. The change in focus has redirected the field of design-driven biotechnology toward what "translational research," which is the buzzword of the era. By definition, translational & applications is "an interdisciplinary branch of the biomedical field supported by three main pillars: bench-side, bedside, and community." Stemming from translational biotechnology came system biology, bioengineering, and so on. Combining such biomedical information from different layers of OMICS-data can ultimately help us in revealing the landscape of molecular mechanisms involved in highly prevalent complex diseases like cancer.

Translational medicine (also referred to as **translational science**) is a discipline within biomedical and public health research that aims to improve the health of individuals and the community by "translating" findings into diagnostic tools, medicines, procedures, policies and education. Translational medicine, area of research that aims to improve human health and longevity by determining the relevance to human disease of novel discoveries in the biological sciences. Translational medicine seeks to coordinate the use of new knowledge in clinical practice and to incorporate clinical observations and questions into scientific hypotheses in the laboratory. Thus, it is a bidirectional concept, encompassing so-called bench-to-bedside factors, which aim to increase the efficiency by which new therapeutic strategies developed through basic research are tested clinically, and bedside-to-bench factors, which provide feedback about the applications of new treatments and how they can be improved. Translational medicine facilitates the characterization of disease processes and the generation of novel hypotheses based on direct human observation.

From: 54-56

whilst integrating platforms of *OMICS*-technologies (Fig. 3)




Figure 3 Multi-OMICS Portfolio: paving the path toward achieving PPM and PPO

Various types of systems data can be generated and integrated with the multi-OMICS integrative analysis. High-throughput OMICS technologies allow the retrieval of comprehensive biological information, whereas computational capabilities enable high-dimensional data modeling and, therefore, accessible and user-friendly visualization. In clinical settings, we need to timely model clinical and multi-OMICS data to find statistical patterns across millions of features to identify underlying biologic pathways, modifiable risk factors, and actionable information that support early detection and prevention of complex disorders, and development of new therapies for better patient care. OMICS analysis have identified clinically actionable mutations, gene and protein expression patterns associated with prognosis, and provided further insights into the molecular mechanisms indicative of cancer biology and new therapeutics for PPO. The integration of multiple biological layers of OMICS studies brought oncology to a new paradigm, from tumor site classification to pan-cancer molecular classification, offering new therapeutic opportunities for PPO and PPM. In this context, Multi-OMICS information leads to a global profiling of health and disease, and providing new approaches for personalized health monitoring and preventive medicine.

From: 19-31, 57-59

PPM, personalized precision medicine; PPO, personalized precision oncology

whose data is analyzed, integrated, mined and clinically interpreted by a set of algorithms and software of bioinformatics (Fig. 4A,B)




Figure 4A,B PPM informatics & Big Data analytics

(A) Classification of enabling tools and techniques in three areas of PPM-driven informatics: clinical informatics, biomedical informatics, and participatory health informatics

(B) Integrated Big Data accumulated from a variety of PPM-dependent sources, including OMICS data, social & behavioral data, environmental data and personal client data (including EMRs and disease story)

Nowadays, the increasing availability of OMICS and related data, due to both the advancements in the acquisition of translational application results and in systems biology simulation technologies, provides the bases for PPM. Success in PPM depends on the access to healthcare and biomedical data. To this end, the digitization of all clinical exams and medical records is becoming a standard in hospitals. The digitization is essential to collect, share, and aggregate large volumes of heterogeneous data to support the discovery of hidden patterns with the aim to define predictive models for biomedical purposes. Patients' data sharing is a critical process. In fact, it raises ethical, social, legal, and technological issues that must be properly addressed. Meanwhile, fragmentation and heterogeneity of available data makes it challenging to readily obtain first-hand information regarding some particular diseases, drugs, genes and variants of interest. So, both medical professionals and IT experts across the globe have started to device computational infrastructural solutions to address the need of timely and precise decision on a patient health issue. It is a high time for both the informatics community and the medical community to collaborate with each other to make a combine effort for achieving the common goal of a better quality patient care. To understand the IT-related viewpoint of how the PPM is implemented, we provided an overview of enabling tools and techniques in three potential areas: biomedical informatics, clinical informatics, and participatory health informatics. The integration of heterogeneous data sources allow to lay the foundations for a series of statistical assessments needed to answer more complex questions that can be used in a variety of fields, such as predictive and precision medicine. In particular, studying the clinical history of patients who have developed similar pathologies we could allow to predict or individuate marks allowing early diagnosis of possible illnesses.

From: 60-63

PPM is a goal of upgraded healthcare of the nearest future to come, in which diagnostic and treatment decisions are informed by each person's unique clinical, OMICS-based, healthcare bu-reaucracy (medical records, etc) (Fig. 5) and environmental (*exposomics*-related) (Fig. 6) information.



Figure 5 Electronic and Sensory Health Records in Clinical Practice and Health Management

Health care informatics focuses on collecting, using, and analyzing data and refers to using data and information technology to improve clinical outcomes and improve both the patient and provider experience. The new applications of public health informatics contribute to more timely and accurate data for disease surveillance. Examples include electronic laboratory reporting of notifiable diseases, aided by new data transmission standards and vocabularies; personal digital assistants or handheld computers to collect data in the field that can be downloaded into a database with no further data entry requirements; geographic information systems integrated with satellite images to provide information about the spread of diseases; use of mobile telephones to report surveillance data from the field; and use of the Internet as an effective way to share surveillance data with health care professionals.

From: 64-66




Figure 6 Exposome-driven human health

Human health is determined by the interaction of our environment with the genome and microbiome, which shape the transcriptomic, proteomic, and metabolomic landscape of cells and tissues. Precision environmental health is an emerging field leveraging environmental and system-level ('omic) data to understand underlying environmental causes of disease, identify biomarkers of exposure and response, and develop new prevention and intervention strategies. The exposome is defined as the totality of internal and external exposures across the lifespan and their health effects. The external exposome includes diet, nutrients, water, chemicals, pollutants, toxins, and other environmental and geospatial exposures. The internal exposome can be measured by untargeted metabolomics, encompassing the small metabolites resulting from all the metabolic processes. Exposomics intended to give a better account of the complex relationships between genes and environmental factors. As a complement to OMICS data, studies on drug-exposome interactions holds immense potential to elevate PPM to an unprecedented level.

From: 64-67

2. PPM-guided clinical oncology practice through the view of bi-omarker-driven approaches

The global goal of PPM is to combine current medicine with molecular breakthroughs to target patients individually and increase the efficacy and effectiveness of the therapeutic strategy. Meanwhile, to secure therapeutic targeting which is crucially important and valuable for the latter, whilst imple-

menting the key PPM-related resources into clinical practice, there is a strong need to develop a principally new approach based on biomarkers-driven targeting aimed at sub-clinical and/or predictive recognition of biomarkers long before the illness (e.g., cancer) clinically manifests itself [68-74] (Fig. 7).




Figure 7 Disease Pathway Bi-omarkers

Molecular pathway maps indicate involvement of multiple molecular mechanisms, and selected biomarker candidates reported as associated with disease progression are identified for specific molecular processes and disease-related stages, including risk factors, screening and diagnosis, and prognosis covering the induction

This new biomarker-driven diagnostic and monitoring technology will create a full digital fingerprint of patient samples that will be able to connect genotype, phenotype, diagnosis, treatment, and outcome at the molecular level. Meanwhile, in PPO, one of the ways to improve the specificity is to move from a single to **multiplex** biomarkers, which can additionally provide significantly increased diagnostic,

predictive and prognostic accuracy. Such multiplex biomarkers should include information from each level of systems biology bridging genomics, transcriptomics, proteomics and metabolomics. This approach would give a real opportunity to secure diagnostic, predictive, and prognostic manipulations [82-87,168] (Fig. 8A-C),




Figure 8A Various roles of biomarkers in cancer treatment

Cancer biomarkers are categorized into several segments based on their utility in various steps of oncology practice, including:

- (i) **diagnostic**: for a confirmed diagnosis of cancer and its extent (are also useful to differentiate between the types of tumors like benign or metastatic tumors, primary or secondary site tumors, etc.);
- (ii) **prognostic**: (help determine the aggressiveness of the detected tumor and how the tumor will respond to the selected therapy - helps physicians to plan and design a proper regimen for the patient);
- (iii) **predictive**: help in the screening of cancer in a healthy patient, and also could predict the risk of getting cancer in the future;
- (iv) **pharmacodynamics**: the circulating biomarkers assess the drug response like its metabolism and deposition in the body during a treatment course, whilst helping to understand the optimum effective dose of the drug;
- (v) **recurrence**: are useful in predicting the recurrence of disease in patients who have undergone treatment and recovered from cancer - periodic screening using assays of the biomarkers helps understand the chances of disease recurrence;
- (vi) **monitoring**: the response of treatment cycles in killing tumor cells -it helps to treat physicians to design future treatment goals.

From: 78-81





Figure 8B,C Cancer biomarker and their clinical applications

Cancer biomarkers are the key to unlocking the promise of PPO, selecting which patients will respond to a more personalized treatment while sparing non-responders the therapy-related toxicity. In cancer, a biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker might be either a molecule secreted by a tumor or it can be a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, and imaging biomarkers can be used for cancer diagnosis, prognosis and epidemiology. Cancer biomarkers must be embedded in the real world of oncology delivery. Cancer biomarkers belong to a variety of bio elements such as DNA, mRNAs, proteins, lnc RNAs, miRNAs, exosomes, cellular metabolites, and organic materials. Cancer patients and pre-cancer persons-at-risk must be placed firmly at the center of a cancer biomarker informed PPO-driven care agenda.

From: 88-93

In this context, cancer biomarkers are any measurable molecular indicator of risk of cancer, occurrence of cancer, or patient outcome. They may include germline or somatic genetic variants, epigenetic signatures, transcriptional changes, and proteomic signatures. These indicators are based on biomolecules, such as nucleic acids and proteins, that can be detected in samples obtained from tissues through tumor biopsy or, more easily and non-invasively, from blood (or serum or plasma), saliva, buccal swabs, stool, urine, etc. Therefore, thousands of species of RNAs, proteins, and metabolites are suggested as candidate tumor biomarkers alone or as constituents of multiplex signatures. If the patient is already diagnosed with a certain cancer, RNA or protein biomarker signatures may help to select a specific therapy or to predict the probability of a relapse. Meanwhile, detection technologies have advanced tremendously over the last decades, including techniques such as next-generation sequencing, nanotechnology, or methods to study circulating tumor DNA/RNA or exosomes.

Along with a significance of single or multi-faceted sets of biomarkers, annotated molecular networks offer new opportunities to understand diseases within a systems biology framework and provide an excellent substrate for network-based identification of biomarkers. The network biomarkers (NBBs) and dynamic network biomarkers (DNBBs) represent new types of bi-omarkers with protein-protein or

gene-gene interactions that can be monitored and evaluated at different stages and time-points during development of disease [169-175]. In this sense, clinical bioinformatics as a new way to combine clinical measurements and signs with human tissue-generated bioinformatics is crucial to translate NBBs and DNBBs into clinical application, validate the disease specificity, and understand the role of biomarkers in clinical settings.

Clinical applications of biomarkers are extensive: much of the current PPM-related designed testing platforms are focused on the identification of protein biomarkers, which are distinct from genetic ones. They can be used as tools for cancer risk assessment, screening and early detection of cancer, accurate diagnosis, patient prognosis, prediction of response to therapy, and cancer surveillance and monitoring response. They have the advantage that they make up the actual molecular phenotype of disease, as they are at the end of the DNA-to-RNA-to-protein progression from genotype to phenotype [94-99].

Biomarker-guided and PPM-driven oncology can make a big difference for patients with cancer and for pre-cancer persons-at-risk. If the clients are not being presented with biomarker-informed testing and treatment options, cancer patients are being unknowingly denied targeted therapeutic possibilities that could help them live longer, healthier lives.

The same principle applies for pre-cancer persons-at-risk who, whilst being avoided biomarker-informed testing, would not be able to secure the cancer prevention.

In this context, novel technologies such as liquid biopsy, CTC screening and monitoring, and companion diagnostics (theranostics) accompanied evolving trends in PPO and prognostic and predictive markers such as minimal residual disease [100-102, 162]. Therefore, they can help to optimize making decisions in clinical practice. Moreover, PPO is needed for newly developed targeted therapies, as they are functional only in patients with specific cancer genetic mutations, and biomarkers are the tools used for the identification of these subsets of patients. So, PPO emerged as a new field encompassing small molecular inhibitors and biologics.

Cancer is a multifaceted and complex disease that results from the disruption of genetic, epi-genetic, and metabolic systems responsible for maintaining physiological conditions in the cell. Cancer is characterized by uncontrollable overgrowth of usually one particular cell type, which becomes a cancer cell, and by spreading of these cancer cells to lymph nodes

and other organs of the body, what is called metastatic disease. So, cancer heterogeneity provides a formidable obstacle to optimizing clinical protocols to achieve durable clinical responses. And the absence of reliable cancer-related biomarkers for the pre-early (subclinical) detection and progression monitoring results in the generation of complex cancer-related molecular pathways negatively impact anticancer immune-mediated responses. As a result, immunotherapy-based therapeutic modalities alone or in combination with other standard or targeted therapies provide limited clinical benefits for patients. Therefore, it is imperative to discover biomarkers suitable for selecting patients most likely to benefit from therapies [103-111].

Biomarkers are crucial for identifying the patients who are expected to derive greatest advantage from canonical targeted therapy, and pre-cancer persons-at-risk who do need a special approach, including preventive therapeutic modes.

In case of cancer, tumor microenvironment plays a crucial role in the process of growth and spreading of cancer cells in the body (Fig 9).




Figure 9 THE TUMOR MICROENVIRONMENT

This simplified illustration of the tumor microenvironment just some of the many different cell types typically present, including tumor cells, vascular cells, immune cells, and others that may or may not be related to the tumor or have a role in tumor promotion or suppression. The patterns of relationships between these different cell types have been shown to correlate with different disease prognoses, with specific "spatial phenotypes" being recognized as characteristic of response to therapy or mortality risk.

Modified from: 182

In this context, PPO describes a diverse set of strategies in cancer medicine tailored to the unique biology of a patient's disease. The adaptability of cancer cells and their intricate interactions with the surrounding microenvironments add another layer of complexity to therapeutic outcomes. But aimed to find the optimal solution and solve the problem. This design of destroying cancer cells while leaving normal cells intact rapidly expanded to most of tumor types. Therefore, strategies range from the use of targeted and/or smart therapies to the use of data from genomic profiling to select treatments independent of cancer type and its microenvironment, and hence go beyond traditional organ-based oncology [112-119,166].

The lack of reliable cancer-related biomarkers not only impedes pre-early (subclinical) detection of cancer but also complicates the assessment of treatment efficacy, necessitating multifaceted approaches for successful management. Therefore, cancer biomarkers are the key to unlocking the promise of PPO-guided trends, selecting which patients or pre-cancer persons-at-risk will respond to a

more personalized treatment while sparing non-responders the therapy-related toxicity. We do emphasize the need for cancer biomarkers infrastructure to be embedded into PPM-driven and PPO-guided health systems of the next step generations. Cancer biomarkers must be embedded in the real world of PPO-guided delivery and testing must be implemented across the civilized medical systems, with the intended aim of narrowing, not widening the inequity gap for patients [161,167,197].

3. PPM-guided individualized strategy to optimize clinical oncology practice and design-driven cancer translational re-search

PPM-guided individualized strategy proves particularly useful in navigating the complexities of cancer cell interactions with their microenvironment, thereby enhancing therapeutic results. Furthermore, PPM has the potential to revolutionize diagnostic procedures, especially for cancers that often go unnoticed in their pre-early stages. The use of targeted biomarkers could facilitate not only early detection but also a more nuanced evaluation of

treatment effectiveness. So, PPM and PPO are thus mostly based on the high-throughput molecular profiling of tumors which allows for the identification of genomic modifications spotlighting appropriate research and therapeutic targeting. A comprehensive understanding of the landscape of genetic alterations in tumors will certainly further advance our understanding of the dynamic interactions between tumor cells and immune subpopulations, resulting in the development of rational combinatorial therapies [167].

In clinical settings, we need to timely model clinical and multi-OMICS data to find statistical patterns across millions of features to identify underlying cancer-related biologic pathways, modifiable cancer risk factors, and actionable information that support early detection and prevention of cancer and pre-cancer conditions, and development of new therapies for better cancer patient care and pre-cancer prevention. Moreover, we are witnessing the transition toward understanding cancer as a continuum by capturing spatial and temporal **tumor heterogeneity** [107-109, 120-127] (Fig. 10).




Figure 10 Inter- and intra-tumor heterogeneity dictates the response to HER2-targeted therapies

Tumor heterogeneity is regarded as a major obstacle to successful PPM and PPO. The lack of reliable response assays reflective of in vivo tumor heterogeneity and associated resistance mechanisms hampers identification of reliable biomarkers. On-treatment biopsies may provide insight into intrinsic or acquired drug resistance. Subsequently, upfront combinatorial treatment or sequential therapy strategies may forestall drug resistance and improve patient outcome. During the course of disease, cancers generally become more heterogeneous. This heterogeneity might result in a non-uniform distribution of genetically distinct tumor-cell subpopulations across and within disease sites (*spatial heterogeneity*) or temporal variations in the molecular makeup of cancer cells (*temporal heterogeneity*).

From: 128-130

In this sense, individual cancer cells can differ with respect to a large number of capabilities, which are regulated at different levels by cell-intrinsic cues, including genetic, epigenetic and proteomic changes. Among the major intrinsic causes of intratumoral heterogeneity are cancer cell migration and invasion, genetic instability, epigenomic/transcriptomic and proteomic regulation, the degree of epithelial-to-mesenchymal transition (EMT) and cell plasticity, as well as the extent of stemness. Tumor microenvironment also contributes to intratumoral heterogeneity through cell-cell interactions and paracrine signaling - cancers describe a clonal increase in the number of cells that will cause a cell to lose control of itself against signals from its environment, allowing it to reproduce independently. One of the biggest reasons for this clonal increase is the genomic changes that occur in both proto-oncogenes and oncogenes.

Tumor heterogeneity, dominating as intratumor one, is considered today as a novel complex biomarker of tumor

progression, metastasis, and immune evasion, and may foster tumor evolution and adaptation and hinder PPM-guided strategies that depend on the outcome from single tumor-biopsy samples. Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges in PPM and PPM-driven biomarker development. And the phenotypic consequences of genetic intratumor heterogeneity would form reflect genomic landscape of the tumor and form the current basis for most biomarker discovery and PPM-guided approaches. Intratumoral heterogeneity evolves in time and space, changes in response to therapy and the development of resistance, and varies between different patients.

Intratumoral heterogeneity is central to the natural selection that drives the processes of carcinogenesis, metastasis and acquired resistance to therapeutic interventions (Fig. 11).




Figure 11 Cancer genetic heterogeneity occurs at multiple levels: between patients, between primary and metastatic tumors in a single patient, and between the individual cells of a tumor

From 157

Intratumor heterogeneity may present profound regulatory and practical clinical challenges when considering such drug combinatorial approaches, faced with a restricted number of drugs active against defined actionable mutations compared with the bewildering potential for diversity within individual tumors. Today's diagnostic, predictive and prognostic technologies applied in hospitals could be implemented through collaborations with basic scientists, translational bi-odesigners and clinicians, and could help pathologists to diagnose tough samples to stage.

One of the challenges of modern precision pathology and PPM-guided oncology is to deal with increasing complexity of modern tissue diagnostics. This might require the analysis of:

(i) multiplex immunofluorescence or FISH screening of proteins and its associated spa-tially resolved genetic

information even on a single slide,

(ii) the integration of other multi-OMICS information including molecular data from next-generation sequencing (NGS), the quantification of 3D-images and the integration of individual patient data from related are-as like radiology, liquid biopsies and the entire diagnostic portfolio.

In this context, precision cancer diagnosis is aiming at detecting individual cancer associated genetic changes amenable to molecularly targeted treatments. This requires first of all a diagnos-tic identification of the presence of cancer cells (circulating tumor cells-CTCs, cancer stem cells-CSCs, etc) in the liquid biopsy taken from the tumor bearing tissue. It also includes the typing and the subtyping of the tumor cell origin and its grading in terms of its likely behavior (Fig 12A,B).




Figure 12A Circulating tumor cells (CTCs) as a predictor and prognostic tool for metastatic cancer and cancer progression

Detection of CTCs in patients with cancer and pre-cancer persons-at-risk is a feasible tool with prognostic potential since increased numbers of CTCs are associated with metastasis and disease progression.

Modified from: Tariki MS, Barberan CCG, Torres JA, Ruano APC, Ferreira Costa DJ, Braun AC, da Silva Alves V, de Cássio Zequi S, da Costa WH, Fay AP, Torrezan G, Carraro DM, Domingos Chinen LT. Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis. *Pathol Res Pract.* 2024 Jan;253:154918. doi: 10.1016/j.prp.2023.154918. Epub 2023 Nov 10. PMID: 37995423

Following the above-mentioned, we would have to stress that the unique example of the newest applications to illustrate subclinical and predictive risks as applicable to tumor progres-sion is **CIRCULATING TUMOR CELLS (CTCs)**. CTCs as a biomarker of the latest generation would make up

a minute fraction of the total number of cells circulating in blood. And the new-est again, Cell Search® method based on a surface expression of epithelial cell adhesion marker (EpCAM), would be able to get the procedure done (178)!




Figure 12B Circulating tumor cells in colorectal, breast and lung cancer CTC detection: valuable tools and predictive biomarkers to refine prognosis

The analysis of circulating tumor cells (CTCs) and CTC clusters in the blood can be used for the pre-early detection of invasive colon, breast and lung cancer. CTCs represent an independent predictor of outcome in patients with metastatic cancer. Moreover, CTCs have a prognostic significance in the monitoring of a malignant disease or the response to targeted cancer therapy.

Modified from: Petrik, J.; Verbanac, D.; Fabijanec, M.; Hulina-Tomašević, A.; Čeri, A.; Somborac-Baćura, A.; Petlevski, R.; Grdić Rajković, M.; Rumora, L.; Krušlin, B.; et al. Circulating Tumor Cells in Colorectal Cancer: Detection Systems and Clinical Utility. *Int. J. Mol. Sci.* 2022, 23, 13582. <https://doi.org/10.3390/ijms232113582>

Giuliano, M., Giordano, A., Jackson, S. et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. *Breast Cancer Res* 13, R67 (2011). <https://doi.org/10.1186/bcr2907>
 Ivanova E, Ward A, Wiegman AP, Richard DJ. Circulating Tumor Cells in Metastatic Breast Cancer: From Genome Instability to Metastasis. *Front Mol Biosci.* 2020 Jul 16;7:134. doi: 10.3389/fmolb.2020.00134. PMID: 32766277; PMCID: PMC7378584
 Tamminga M, de Wit S, Schuurin E, Timens W, Terstappen LWMM, Hiltermann TJN, Groen HJM. Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy. *Transl Lung Cancer Res.* 2019 Dec;8(6):854-861. doi: 10.21037/tlcr.2019.11.06. PMID: 32010564; PMCID: PMC6976367

Meanwhile, along with **CTCs**, **cancer stem cells (CSCs)** represent the other main target of the current efforts to eradicate cancer because of their ability to promote metastatic dissemination and to survive cytotoxic therapies. Whilst keeping in mind the role of the tumor microenvironment playing an active role in supporting tumor progression and greatest impact in the crosstalk between CSCs and the host immune system to allow for developing effective

therapeutic strategies targeting the ability of CSCs to escape immune-surveillance through immune editing (179-182).

CSCs, a small subset of cells in tumors that are characterized by self-renewal and continuous proliferation, lead to tumorigenesis, metastasis, and maintain tumor heterogeneity. Cancer continues to be a significant global disease burden (Fig 13A,B).




Figure 13A Circulating tumor cells in colorectal, breast and lung cancer CTC detection: valuable tools and predictive biomarkers to refine prognosis

The analysis of circulating tumor cells (CTCs) and CTC clusters in the blood can be used for the pre-early detection of invasive colon, breast and lung cancer. CTCs represent an independent predictor of outcome in patients with metastatic cancer. Moreover, CTCs have a prognostic significance in the monitoring of a malignant disease or the response to targeted cancer therapy.

Modified from: 182,183




Figure 13B The cancer stem cell (CSC) theory of tumor development and relapse initiation

An initial oncogenic event (solid arrow) occurring in a normal cell may create a precancerous cell, or directly result in malignant transformation. The oncogenic event is likely to require a number of supporting genetic/epigenetic events (hashed arrows). By the point of clinical diagnosis, the heterogeneous tumor contains cells which have, or are able to activate their stem cell program and may be able to evade standard therapy. Any CTCs evading therapy are able to divide and differentiate to repopulate the tumor.

Modified from: 182,183

CSCs are a subpopulation of cancer cells with many clinical implications in most cancer type, including their role in cancer metastases and causing treatment resistance and recurrence in cancer. The discovery of CSCs has provided

many new insights into the complexities of cancer therapy: tumor initiation, treatment resistance, metastasis, recurrence, assessment of prognosis and prediction of clinical course. Thus, many different therapeutic approaches

are being implemented for prevention and treatment of cancer recurrence. Commonly used methodologies for detection and isolation of CSCs include the use of different surface biomarkers. Overall, given their significance in cancer biology, refining the isolation and targeting of CSCs will play an important role in future management of cancer and development of PPO (183-188). Thus, shedding light on this problem could contribute significantly to our general understanding of how tumors are formed and further the development of new treatment strategies (163,167).

As you might see from the above-mentioned, clinical evaluation of tumor heterogeneity is an emergent issue to improve PPM-guided clinical oncology, since this phenomenon is closely related to cancer progression, resistance to therapy, and recurrences. A quantitative measure of genetic heterogeneity based on next-generation sequencing (NGS) data and mutant-allele tumor heterogeneity have been developed and applied to a Big Data set (166,194).

In particular, reliable and accurate NGS technologies have a very large promise to accelerate PPM and PPM-guided clinical oncology practice. Currently, NGS can speed up in the pre-early diagnosis of cancer and discover pharmacogenetic markers that help in personalizing cancer therapies. NGS holds the added advantage of providing more comprehensive picture of cancer landscape and uncovering cancer development pathways. (176,177,194).

The latter would strongly request the proper feedback – would that measure correlate with clinical outcome or... not? From a practical point of view, analytical methods that are widely accessible today, or will be in the near future, are evaluated to investigate the complex pattern of intratumor heterogeneity in a reproducible way for a clinical application. Moving forward, improved computational methods to better dissect clonal architecture and model tumor clonal dynamics, as well as studies examining tumors with finer resolution through the use of deeper sequencing depth, single-cell samples, or multiple tumor regions, will help

to elucidate the impact intratumor heterogeneity has on a tumor's features and potential. Continuing such studies will lead to an improved understanding of the above-mentioned phenomenon and clonal dynamics, endowing us with the ability to more fully decipher the evolutionary history of a tumor as well as a greater understanding of which events are truly clonal and how a tumor may respond to therapy. This will potentially translate into novel biodesign-driven therapeutic approaches and inform new ways to best stratify groups of cancer patients and pre-cancer persons-at-risk for maximal treatment or preventive prophylactic efficacy.

By integrating multiple data sources (multi-OMICS), each case of cancer can be approached as if it represents a separate disease. The notion of PPO takes on new meanings as new levels of data are added to the understanding of cancer, from complex biological, digital, clinical, behavioral, and environmental data (167).

Cancer induction and progression through the vies of PPO start from the symptoms and eve-rything that can be seen with the doctor's naked eye, and the resolution increases through the development of microscopy, biochemistry, cell biology, and the birth of pharmacogenetics. And the cancer-related disorder begins to be reclassified starting from molecules to symptoms; it is the stage in which the notions of biomarkers and targeted therapies gain momentum. Precision in this period is based on deciphering the structure of DNA and the early stages of biotechnology development. Later, PPO is dominated by the development of high-capacity genomic sequencing technologies, with comprehensive genomic profiling, shifting the gears toward genomic medicine and modern biotechnology, which today underpins the development of most drugs. And, finally, in the latest version of PPO, the characterization of cancer will be of very high resolution (single-cell multi-OMICS); it will be dynamic (the transition from pre-cancer to cancer will be predictable), comprehensive (multi-OMICS biomarkers, functional tests, multi-target drugs, hybrid pharmacological constructs), and data-driven (network medicine, IT assisted decision-making tools, etc) (Fig 14).




Figure 14 Biomarker integration in PPM

Biomarkers are used extensively in PPM-guided practice for screening, diagnosing, and characterizing diseases. Biomarker analysis has started the shift toward an individualized treatment for each patient, and, as such, biomarker discovery is of high importance in this approach.

From <http://biorender.com> with modifications

The integration of OMICS technologies, biomarker-driven platforms and IT-assisted algorithms into healthcare presents a transformative potential for PPM and PPM-guided patient care. These methods offer numerous advantages,

such as improved diagnostic accuracy, tailored treatment plans, and enhanced patient monitoring (167).

Among these methods, *in silico* approaches, which involve

computer simulations and model-ing, are gaining traction, reducing the need for time-consuming physical examination, speeding up drug development, and enhancing disease understanding. They also hold promise for conducting virtual clinical trials, which can streamline the evaluation of medical interventions. User-friendly, seamless integration with existing healthcare systems and clear insights are crucial for broad adoption.

4. PPO as a new and upgraded field in development of PPM-guided clinical oncology

The field of PPO is rapidly being transformed by emerging technologies based on IT al-gorithms and bioanalytics approaches, that are enabling a more efficient and accurate analysis of large amounts of data sources with different modalities. Whilst assisting in identifying novel biomarker-driven therapeutic targets and predict treatment responses, and leading to more PPM-guided treatment decisions for cancer patients and pre-cancer persons-at-risk (Fig 15).




Figure 15 The main measures adopted within PPM-guided cancer medicine

PPM-guided cancer medicine or Personalized & Precision Oncology (PPO) is a multidisciplinary team effort that requires involvement and commitment of many. Building on the success of significant advances in precision therapy for oncological patients, future developments will be shaped by improvements in scalable OMICS diagnostics in which increasingly complex multilayered datasets require transformation into clinically useful information guiding patient management at fast turnaround times. Adaptive profiling strategies involving tissue- and liquid-based testing that account for the immense plasticity of cancer during the patient's journey and also include early detection approaches are already finding their way into clinical routine and will become paramount. A second major driver is the development of smart clinical trials and trial concepts which, complemented by real-world evidence, rapidly broaden the spectrum of therapeutic options. Tight coordination with regulatory agencies and health technology assessment bodies is crucial in this context. Multicentric networks are key in implementing precision oncology in clinical practice and support improving the ecosystem and framework needed to turn invocation into benefits for patients. Modified from: 188

Meanwhile, establishing therapy options and managing cancer treatments in the context of data from multi-OMICS manipulations is believed to be urgently necessary, and this view accel-erates the implementation of PPM-related resources in oncology, resulting in PPO [131,168]. On a clinical PPO-related perspective, integrative analysis of multiple OMICS data gives a focus to functional targets being highly valuable for clinical translation. The integration of multiple bio-logical layers of OMICS data brought PPO to a new paradigm, from tumor site classification to pan-cancer molecular classification, offering new therapeutic opportunities for precision medi-cine. On a more basic point of view, integrative data analysis heightens the OMICS fields, ena-bles the oncogenic processes to be comprehensively interrogated, leading to a broader under-standing of tumor biology and opening the way to integrative tumor model development, whilst dramatically accelerating the identification of robust biomarkers toward the development of tai-lored cancer therapy. The latter is an effective strategy to fight cancers by bridging OMICS tech-nologies, IT resources and drug discovery trends to provide specific treatment for patients and preventive prophylaxis for pre-cancer persons-at-risk (both with different genetic characteris-tics). And not only efficacy but also the adverse effects of drugs on cancer patients or pre-cancer persons-at-risk should be taken into account during the treatment [132,133,166-168].

In this sense, PPO is evidence-based, individualized medicine that delivers the right care to the right cancer patient at the right time and results in measurable improvements in outcomes and a reduction on health care costs.

The essence of PPO lies in the use of biomarkers of different levels and specificities, ob-tained from tissue, serum, urine or imaging. Those tools for implementing PPO resources based on molecular diagnostic and interventions will improve cancer prevention. Molecular diagnostics identify individual cancer patients who are more likely to respond positively to targeted thera-pies. The use of companion molecular diagnostics or theranostics is expected to grow significant-ly in the future and will be integrated into new cancer therapies a single (bundled) package which will provide greater efficiency, value and cost savings. This approach represents a unique oppor-tunity for integration, increased value in PPO.

Globally, PPM has revolutionized approaches to treatment in the field of cancer by enabling therapies to be specific to each patient and pre-cancer persons-at-risk. However, physicians en-counter an immense number of challenges in providing the optimal treatment regimen for the individual given the sheer complexity of clinical aspects such as tumor molecular profile, tumor microenvironment, acquired or inherent resistance mechanisms, risks for the development of metastases, the limited availability of biomarkers and the choice of combination therapy. The integration of innovative next-generation technologies via bioinformatics-driven platforms has the potential to transform the field by supporting clinical decision making in cancer treatment and the delivery of precision therapies while integrating numerous clinical considerations.

The above-mentioned unique opportunity allowed for identification of areas where cancer patients, pre-cancer persons-at-risk, the parents, and physicians are

communicating effectively, and also where there is a teachable gap in the profiled education. Furthermore, surveying physicians about the advantages and roadblocks they experience with biomarker testing provided valuable information on ways to improve the delivery of PPM-guided resources to provide personalized care and ultimately enhance care for canonical patients and pre-cancer persons-at-risk individually.

Globally, cancer patient and pre-cancer person-at-risk, and physician responses indicated that a particular pair of clients are aware of basic tumor biology and treatments, and thus are exposing their willingness to participate in personalized and precision care. It is of interest that physicians misjudged client responses, and this may reflect an opportunity to improve the dialogue between cancer patients and pre-cancer persons-at-risk on one hand, and physicians, on the other one. Regarding the latter, it is time to stress that in the future, the development of blood-based rather than tissue-based methods for the detection of tumor biomarkers may help increase the willingness of cancer patients and pre-cancer persons-at-risk to participate in personalized care even further. With much less invasive and more convenient testing procedures, both doctors and their cancer-related clients may participate more fully in personalized care.

The latter means that multi-faceted collaboration with healthcare professionals, educators, and technology experts will be essential to developing systems that meet the needs of both clinicians and patients, as well as for persons-at-risk and their relatives. It also is essential for stakeholders to work collaboratively to navigate these challenges and create an environment that supports innovation while safeguarding ethical principles and patient rights.

In this context, high-throughput OMICS technologies and IT-assisted algorithms and tools allow the retrieval of comprehensive and holistic biological information, whereas computational capabilities enable high-dimensional data modeling and, therefore, accessible and user-friendly visualization. Rapid advances in high-throughput technologies of biomedical informatics aspects such as database storage and big data management, integration of OMICS within EHR, and interoperability have the potential to increase the weight of PPO and PPM as a whole within clinical cancer practice. The proposed architecture could improve the potentialities of data routinely collected in many health information systems to form a patient-centered information environment [134,135,165,166].

Furthermore, bioinformatics has enabled comprehensive multi-OMICS and clinical data integration for insightful interpretation [134,136,137,166].

5. OMICS-driven and IT-supported Resources as Sets of Crucial Tools to Fight Cancer

The development of PPO-guided and OMICS-supported

cancer care is predicted to lead to better outcomes and reduced risk of side effects for patients with cancer as well as reducing costs and improving efficiencies for healthcare systems [168].

In this context, genetic testing, profiling and enhanced genomic analysis have had a profound impact on the way in which tumors are evaluated and classified. A number of new drugs, including vemurafenib and dabrafenib, which target proteins that prevent the immune system attacking cancer cells, have been developed as a result of this discovery [138]. Among a variety of the alternative genetic tests, let me stress that predictive genetic testing is really a crucial and valuable type of testing used to look for inherited gene mutations that might put a person at higher risk of getting certain kinds of cancer. This type of testing might be suggested for:

- (i) a person with a strong family history of certain types of cancer;
- (ii) a person already diagnosed with cancer; and
- (iii) family members of a person known to have an inherited gene mutation that increases their risk of cancer.

Prognostic biomarkers associate host and tumor variables with clinical outcomes independent of treatment, showcasing how aggressive a tumor is likely to be [139-141]. These biomarkers have an impact on the prognosis of cancer patients or pre-cancer persons-at-risk regardless of treatment, predicting the mean clinical outcome of a patient. They can be used to stratify randomization by disease risk, thus minimizing heterogeneity within the subgroup and maximizing heterogeneity across subgroups; to identify potential treatment targets; and to direct treatment to specific patient subgroups.

After the genetic information obtained and thus is available, the client (cancer patient or pre-cancer person-at-risk) would contact genetic counseling service for making the final CD making. Before and after genetic testing, genetic counseling can help you understand your risk of developing cancer and pre-select the options to minimize this risk. Moreover, family cancer centers can advise you about your risk of developing cancer, provide genetic counselling and medical advice and, in some situations, comprehensive genetic testing.

PPM-guided cancer practice is founded and has evolved largely on the basis of biomarker-directed predictive cancer therapy. The strength of this association has grown to such an extent that the use of predictive biomarker tests to guide the therapy for individual cancer patients has become the cornerstone of PPM. The implementation of PPM-guided cancer diagnostic technologies and PPO-related resources through OMICS-guided profiling technologies has increasingly been integrated with standard clinical-pathological evaluations to enhance diagnosis, prognostication, and prediction of clinical outcomes (Fig.16).




Figure 16 PPM-guided service in cancer practice

Samples (e.g., serum/tissue/urine/feces) can be analyzed by multi-OMICS technologies. Blood informs on the systemic response to the disease, urine includes the host metabolites which are excreted from the body, stool samples show what the intestine is exposed to and resected tissue can give information on the response mounted at the site of disease. Information from multi-OMICS analyses, clinical reports, lifestyle and psychosocial characteristics can identify biomarkers for prevention, diagnosis, prognosis and surveillance, and help to determine the most suitable therapeutic schedule for individuals presenting with a given disease.

Modified from: 189

Precision cancer pathology including **immunohistochemistry (IHC)** and **fluorescence in situ hybridization (FISH)** for cancer biomarker analysis in routine pathology practice, has therefore become fundamental not only to inform on tumor diagnosis and prognosis but also to drive therapeutic decisions in daily practice.

In this context, **pharmacogenomics (PGx)** is one of the most important components of PPO, which focuses on the association between genetic variations and drug response. PGx can help oncologists decide drug selection, dose adjustment, and treatment period and prevent adverse drug reactions. Specific genetic variations have been

related to clinically significant changes in drug disposition between individuals, including vulnerability to adverse drug responses and therapeutic response or efficacy. There is a substantial amount of scientific evidence supporting the utility of pharmacogenomics testing in cancer patient management [142-147,168].

PGx testing (Fig. 17) is aimed at tailoring cancer drug therapy at a dosage that is most appropriate for an individual cancer patient or a pre-cancer person-at-risk, with the potential benefits of increasing the clinical efficacy and individualized safety.




Figure 17 Predictive DNA testing in cancer practice

Pharmacogenomic tests can be used to predict and to target medicines to good responders or to identify whether an individual has an increased risk of a specific adverse drug reaction from a particular medicine

Modified from: 190-192

This scenario illustrates the fundamental idea behind PPM and PPO: coupling established clinical-pathological indexes with state-of-the-art molecular profiling to create diagnostic, prognostic, and therapeutic strategies precisely tailored to each patient's requirements. Recent design-inspired biotechnological advances have led to an explosion of cancer-relevant molecular information, with the potential for greatly advancing patient care [163,165,167].

In reality, PPO is an emerging approach for tumor treatment and prevention that takes into account inter- and intra-tumor variability in genes, tumor (immune) environment, and lifestyle and morbidities of each person diagnosed with cancer (including pre-cancer person-at-risk). PPM-driven

PPO-armed cancer therapy have the potential to tailor therapy towards the oncogenic drivers of the tumor and modulate the tumor immune environment. Furthermore, PPO aims to optimize tumor response, thereby taking into account the therapy-induced toxicities for each specific patient. In this way, optimized tumor response is combined with the preservation of organ function and, thus, quality of life. Moreover, this ensures better patient care in the end, which is, of course, what it aims for [168].

Approaches to PPM-guided areas of clinical oncology and cancer therapy can generally be categorized into biomarker-driven targeted **diagnostic techniques, data integration methods, and treatment modalities (Fig 18)**.




Figure 18 Patient centered personalized care for cancer treatment and PPM-guided cancer care

To understand the unique molecular make-up of each patient, biopsy samples are analyzed via different sequencing techniques, (including genetic, epigenetic, RNA and ncRNA sequencing) and through medical imaging/histological analysis. These techniques potentially reveal the different pharmacogenomic markers commonly altered in different cancer types, including but not limited to, KRAS, BRCA1/2, EGFR, HLA-B, ALK, PIK3CA, B-RAF, VHL, BCR-ABL1, PTEN, TP53. Additionally, different molecular patterns, biomarkers or integrated panels are also analyzed, serving as predictive or diagnostic signatures. These include, but are not limited to, dMMR (deficient DNA mismatch repair)/MSI-high (microsatellite instability-high), TMB (tumor mutation burden), RET (RE-arranged during Transfection) genetic fusion, NTRK (neurotrophic tyrosine receptor kinase gene) fusion, PD-1/PD-L1 (Programmed Cell Death Protein 1 and Programmed Cell Death Ligand 1), T-cell or B-cell focused gene signature profile, PSA (prostate-specific antigen), GEP (T cell-inflamed gene expression profile), tumor imaging and histology. AI/ML is used for a myriad of functions such as sorting the markers, screening across real world data (RWD), generating prognostic models, risk prediction, selecting specific targets, and testing drug combinations. Patient-derived data (based on tested samples and medical history) is curated and streamlined not only for specific clinical trial design, but also to record, statistically analyze, and compare the results.

From: 158-160,198

Meanwhile, multi-OMICS screening for biomarkers, bioanalytic approaches, and bioinformatics-assisted algorithms synthesize diverse transdisciplinary biological and clinical data to provide a comprehensive view of the cancer landscape. Beyond traditional OMICS techniques, the field is rapidly expanding into medical imaging techniques, which utilize large-scale digital archives for cancer diagnosis, integrating medical molecular imaging with genomics to deepen our understanding of cancer mechanisms and biomarker discovery. Treatment modalities include targeted therapies and immunotherapies, which tailor drug treatments according to the individual characteristics of each tumor (164,167).

Open-access databases could facilitate the above-mentioned, allowing cancer practitioners to contribute to and access data for bioanalytics and more comprehensive studies, whilst requesting algorithms of the next-step generation, capable of handling the heterogeneity in multi-OMICS data, to provide a holistic but evidence-based and clinically valuable view of cancer.

One of the crucially valuable and innovation combinatorial (diagnostic-predictive-prognostic-therapeutic) areas of PPO - panels of upgraded tools (companion diagnostics and theranostics as tests and medicines) used to identify specific biomarkers and profiled targets of a disease, or disease susceptibility and aimed to lead us to the approach of PPO (162). In this context, evidence-based clinical guidelines

increasingly include biomarker-driven OMICS profiling, and recent evidence suggests that PPO can be delivered in a cost-effective way for health systems. Therefore, precision OMICS testing for cancer biomarkers supported by IT algorithms and tools, must be embedded into the clinical practice of PPO-guided care delivery going forward (197).

For instance, PPO-driven therapies, including tumor-infiltrating lymphocytes that are extracted from a patient's melanoma and eventually reinfused into the patient, as well as mRNA vaccines used to target neoantigens unique to a patient's tumor, show great promise. Improvements in accompanying imaging modalities have allowed for accurate staging of disease and assessment of treatment response. Continued growth in the role of molecular imaging in the evaluation of melanoma, including the incorporation of IT algorithms into image interpretation and use of radiolabeled tracers allowing for intricate imaging of the tumor immune microenvironment, is expected in the coming years (195).

Another trend in PPO is the development of personalized vaccines presenting multifaceted challenges. The potential of personalized vaccines to optimize responses and mitigate disease burden underscores the significance of ongoing research and collaboration in advancing PPM- and PPO-guided resources in immunization (196).

Moreover, PPO presents principally new opportunities for patients with cancer and pre-cancer persons-at-risk as well,

whilst emerging as the tumor treatment and prevention that consider the cancer variability in terms of gene expression patterns, tumor specific (immune) micro-environment, and patients' particular lifestyles and morbidities, covering huge Data Sets! As PPO introduces a Big Data analysis of PPO-guided OMICS approaches, there are still challenges in the translation of all these data into meaningful and equitable benefits to patients and health care. And thus each patient presents its specific preferences, needs, tolerances, and unique tumor vulnerabilities even when suffering from very similar diseases or course of treatment, which demands and highlight the importance of the PPO approach and the personalized cancer or pre-cancer care. In reality, it is time to recognize the possibility that advanced computer implementation could generate real-world data that expand our understanding of cancer, rapidly identify new treatments, and create personalized drugs or immune therapies (166,168).

This perspective fosters the development of specialized treatments for each specific subtype of cancer, based on the measurement and manipulation of key patient OMICS data. And the field of systems biology, design-driven biotech and translational applications would thus aid in the development of diagnostic and therapeutic tools and medicines of the next step generation by analyzing data from preclinical and clinical studies. This approach is used to develop predictive and prognostic tools that replicate biological systems in order to characterize their behavior and response in the context of disease and drug development. This is particularly relevant to forthcoming cancer treatments, as a significant portion of oncology drugs in development are personalized medicines. PPM therapies that are currently being developed include cancer vaccines, mAbs, and CAR T-cells [148].

Conclusion

Following the above-mentioned, we would stress that effective data management is becoming crucial to ensure the success of PPM-guided cancer research and oncology clinical practice.

Moreover, international collaborations and productive partnership in cancer research are essential for addressing the global burden of cancer. Initiatives that bring together researchers, biodesigners and bioengineers, clinicians, and public health experts can facilitate the sharing of knowledge and resources. These collaborations can help develop strategies that are culturally relevant and effective in different populations, ultimately improving cancer care worldwide.

Simultaneously, PPM-guided oncology is gaining traction as research continues to uncover the genetic and environmental factors that contribute to individualized cancer risk. Strategies aimed at prevention, including lifestyle modifications, personalized cancer vaccination, and scheduled screenings, are critical in reducing the incidence of cancer.

Meanwhile, the capacity to build relationships within the

bioindustry is important, as it can help to foster collaborations and facilitate the development and implementation of new PPM-driven technologies in daily cancer practice. Beyond the fragmentation in fostering bridging connections, a recurring observation from multiple stakeholders is the fragmented nature of the relationship between research, healthcare, industry, government, and patients. There are multiple obstructions, or lack of capacities, resulting in divides in the continuum from research to healthcare.

Pooling common resources across stakeholders is essential for advancing translational research in PPM-driven cancer practice. Bringing together biodesigners, researchers, healthcare providers, and other stakeholders, can leverage the collective expertise and resources to accelerate the development of new treatments and therapies. Meanwhile, a lack of medical guidelines has been identified by the majority of responders as the predominant barrier for adoption, indicating a need for supporting the implementation of PPO! Implementation of the latter, being paired and integrated in one and new entity, require a lot before the current model "physician-patient" could be gradually displaced by a new model "medical advisor-healthy person-at-risk". This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM to elicit the content of the new branch.

PPM plays a central role in oncology, providing targeted solutions to complex challenges. By employing cutting-edge diagnostic, predictive and prognostic techniques, data analytics and treatment modalities aimed at revolutionizing cancer care - making it more tailored, effective and safer - PPM-driven approaches stand to revolutionize cancer treatment paradigm (167).

A major challenge in PPO lies in establishing the relationship between biological data, disease, design-driven biotech and clinical translation: how can we interpret "Big Data," referring to the greater collection of healthcare data across thousands of patients and pre-cancer persons-at-risk, involving the tracking of various medical indicators and biomarkers (primarily clinical and OMICS data). collected to make meaningful medical decisions? High-throughput data collection enables researchers, biodesigners and bioengineers to screen tissues for thousands of molecular targets, effectively capturing the response of a complex system over time. Statistically interpreting trends from Big Data is a discipline unto itself and is necessary for predictive modeling and clinical decision support [149-157,166,167]. Rare cancers pose unique challenges for patients and their physicians arising from a lack of information regarding the best therapeutic options. Physicians are increasingly using genetics to identify cancer patients or persons-at-risk at high risk for certain cancers to allow for pre-early detection or prophylactic interventions. Genomic analysis is used to inform prognosis and more accurately establish a diagnosis, as well as to expose therapeutic targets for which drugs are currently available and approved for personalized use.

Transforming how we think about cancer care delivery requires engagement of multidisciplinary clinical, population health and health systems partners, community and patient advocates, health informatics experts, health policymakers, and bureaucrats to develop and test novel solutions in rapid cycles of quality improvement and to rigorously conduct implementation research.

PPO as the trend toward PPM in oncology continues, coordination of all health care stakeholders has become more important than ever. Oncologists, pathologists, and payers must work with pharmaceutical, biotech and diagnostic companies to develop products, services, and coverage policies that improve patient outcomes and, as we have begun to see, lower overall health care costs for institutions that put personalized regimens in place.

References

1. van Renterghem AWJ, van de Haar J, Voest EE. Functional precision oncology using patient-derived assays: bridging genotype and phenotype. *Nat Rev Clin Oncol*. 2023 May;20(5):305-317. doi: 10.1038/s41571-023-00745-2. Epub 2023 Mar 13. PMID: 36914745.
2. Yoon H, Lee S. Integration of Genomic Profiling and Organoid Development in Precision Oncology. *Int J Mol Sci*. 2021 Dec 25;23(1):216. doi: 10.3390/ijms23010216. PMID: 35008642; PMCID: PMC8745679.
3. Letai A, Bhola P, Welm AL. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. *Cancer Cell*. 2022 Jan 10;40(1):26-35. doi: 10.1016/j.ccell.2021.12.004. Epub 2021 Dec 23. PMID: 34951956; PMCID: PMC8752507
4. Brown NA, Elenitoba-Johnson KSJ. Enabling Precision Oncology Through Precision Diagnostics. *Annu Rev Pathol*. 2020 Jan 24;15:97-121. doi: 10.1146/annurev-pathmechdis-012418-012735. PMID: 31977297.
5. Fujiwara Y, Kato S, Kurzrock R. Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards. *Surg Oncol Clin N Am*. 2024 Apr;33(2):197-216. doi: 10.1016/j.soc.2023.12.004. Epub 2023 Dec 18. PMID: 38401905; PMCID: PMC10894322.
6. Incorvaia L, Russo A, Cinieri S. The molecular tumor board: a tool for the governance of precision oncology in the real world. *Tumori*. 2022 Aug;108(4):288-290. doi: 10.1177/030089162111062266. Epub 2021 Dec 17. PMID: 34918610.
7. Bilkey GA, Burns BL, Coles EP, Mahede T, Baynam G, Nowak KJ. Optimizing Precision Medicine for Public Health. *Front Public Health*. 2019 Mar 7;7:42. doi: 10.3389/fpubh.2019.00042; Ashley EA. The precision medicine initiative: a new national effort. *JAMA*. (2015) 313:2119-20
8. Weeramanthri TS, Dawkins HJS, Baynam G, Bellgard M, Gudes O, Semmens JB. Editorial: precision public health. *Front Public Health*. (2018) 6:121. 10.3389/fpubh.2018.00121
9. Martin-Sanchez F, Lázaro M, López-Otín C, Andreu AL, Cigudosa JC, Garcia-Barbero M. Personalized Precision Medicine for Health Care Professionals: Development of a Competency Framework. *JMIR Med Educ*. 2023 Feb 7;9:e43656
10. Alvarez, M.J.R. (2022). Precision Public Health Perspectives. In: Hasanzad, M. (eds) Precision Medicine in Clinical Practice. Springer, Singapore. https://doi.org/10.1007/978-981-19-5082-7_7
11. Traversi, D.; Pulliero, A.; Izzotti, A.; Franchitti, E.; Iacoviello, L.; Gianfagna, F.; Gialluisi, A.; Izzi, B.
12. Agodi, A.; Barchitta, M.; et al. Precision Medicine and Public Health: New Challenges for Effective and Sustainable Health. *J. Pers. Med*. 2021, 11, 135. <https://doi.org/10.3390/jpm11020135>
13. Stefanicka-Wojtas D, Kurpas D. Personalised Medicine Implementation to the Healthcare System in Europe (Focus Group Discussions). *Journal of Personalized Medicine*. 2023. 13: 380.
14. Ahmed Z. Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis. *Hum Genomics*. 2020 14: 35
15. McAlister FA, Laupacis A, Armstrong PW. Finding the right balance between precision medicine and personalized care. *CMAJ*. 2017 Aug 21;189(33):E1065-E1068. doi: 10.1503/cmaj.170107. PMID: 28827437; PMCID: PMC5566606.
16. Delpierre C, Lefèvre T. Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. *Front Sociol*. 2023 Feb 21;8:1112159. doi: 10.3389/fsoc.2023.1112159. PMID: 36895332; PMCID: PMC9989160.
17. Nielsen J. Systems Biology of Metabolism: A Driver for Developing Personalized and Precision Medicine. *Cell Metab*. 2017 Mar 7;25(3):572-579
18. Hoeben A, Joosten EAJ, van den Beuken-van Everdingen MHJ. Personalized Medicine: Recent Progress in Cancer Therapy. *Cancers (Basel)*. 2021 Jan 11;13(2):242
19. Larance M & Lomond AI Multidimensional proteomics for cell biology. *Nat. Rev. Mol. Cell. Biol* 16, 269-280 (2015)
20. Han XM, Aslanian A & Yates JR Mass spectrometry for proteomics. *Curr. Opin. Chem. Biol* 12, 483-490 (2008)
21. Duarte TT & Spencer CT Personalized proteomics: The future of precision medicine. *Proteomes* 4, (2016)
22. Gregorich ZR & Ge Y Top-down proteomics in health and disease: Challenges and opportunities. *Proteomics* 14, 1195-1210 (2014)
23. Sidoli, S., Lu, C., Coradin, M. et al. Metabolic labeling in middle-down proteomics allows for investigation of the dynamics of the histone code. *Epigenetics & Chromatin* 10, 34 (2017). <https://doi.org/10.1186/s13072-017-0139-z>
24. Monteiro MS, Carvalho M, Bastos ML & Guedes de Pinho P Metabolomics analysis for biomarker discovery: Advances and challenges. *Curr. Med. Chem* 20, 257-271 (2013)
25. Roessner U & Bowne J What is metabolomics all about? *Biotechniques* 46, 363 (2009)
26. Everett JR, Loo RL & Pullen FS Pharmacometabonomics

- and personal-ized medicine. *Ann. Clin. Biochem* 50, 523–545 (2013)
27. Luvhengo TE, Bombil I, Mokhtari A, Moeng MS, Demetriou D, Sanders C, Dlamini Z. Mul-ti-Omics and Management of Follicular Carcinoma of the Thyroid. *Biomedicines*. 2023 Apr 19;11(4):1217. doi: 10.3390/biomedicines11041217. PMID: 37189835; PMCID: PMC10135557.
28. Medori MC, Micheletti C, Gadler M, Benedetti S, Guerri G, Cristofoli F, Generali D, Donofrio CA, Cominetti M, Fioravanti A, Riccio L, Bernini A, Fulcheri E, Calogero AE, Cannarella R, Stuppia L, Gatta V, Cecchin S, Marceddu G, Bertelli M. Omics sciences and precision medicine in prostate cancer. *Clin Ter*. 2023 Nov-Dec;174(Suppl 2(6)):95-103. doi: 10.7417/CT.2023.2476. PMID: 37994753.
29. Lai B, Fu J, Zhang Q, Deng N, Jiang Q, Peng J. Artificial intelligence in cancer pathology: Challenge to meet increasing demands of precision medicine. *Int J Oncol*. 2023 Sep;63(3):107. doi: 10.3892/ijo.2023.5555. Epub 2023 Aug 4. PMID: 37539741.
30. Jose A, Kulkarni P, Thilakan J, Munisamy M, Malhotra AG, Singh J, Kumar A, Rangnekar VM, Arya N, Rao M. Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine. *Mol Cancer*. 2024 Mar 9;23(1):50. doi: 10.1186/s12943-023-01916-6. PMID: 38461268; PMCID: PMC10924370.
31. Dar MA, Arafah A, Bhat KA, Khan A, Khan MS, Ali A, Ahmad SM, Rashid SM, Rehman MU. Multiomics technologies: role in disease biomarker discoveries and therapeutics. *Brief Funct Genomics*. 2023 Apr 13;22(2):76-96. doi: 10.1093/bfpg/elac017. PMID: 35809340.
32. Nafees A, Khan M, Chow R, Fazelzad R, Hope A, Liu G, Letourneau D, Raman S. Evaluation of clinical decision support systems in oncology: An updated systematic review. *Crit Rev Oncol Hematol*. 2023 Dec;192:104143. doi: 10.1016/j.critrevonc.2023.104143. Epub 2023 Sep 22. PMID: 37742884.
33. Beeler PE, Bates DW, Hug BL. Clinical decision support systems. *Swiss Med Wkly*. 2014 Dec 23;144:w14073. doi: 10.4414/smww.2014.14073. PMID: 25668157.
34. Mukherjee T, Pournik O, Lim Choi Keung SN, Arvanitis TN. Clinical Decision Support Systems for Brain Tumour Diagnosis and Prognosis: A Systematic Review. *Cancers (Basel)*. 2023 Jul 6;15(13):3523. doi: 10.3390/cancers15133523. PMID: 37444633; PMCID: PMC10341227.
35. Syrowatka A, Motala A, Lawson E, Shekelle P. Computerized Clinical Decision Support To Prevent Medication Errors and Adverse Drug Events: Rapid Review. 2024 Feb. In: *Making Healthcare Safer IV: A Continuous Updating of Patient Safety Harms and Practices [Inter-net]*. Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 Jul-. PMID: 38381911.
36. Hendriks MP, Jager A, Ebben KCWJ, van Til JA, Siesling S. Clinical decision support systems for multidisciplinary team decision-making in patients with solid cancer: Composition of an implementation model based on a scoping review. *Crit Rev Oncol Hematol*. 2024 Mar;195:104267. doi: 10.1016/j.critrevonc.2024.104267. Epub 2024 Feb 3. PMID: 38311011.
37. Kohut K, Morton K, Turner L, Shepherd J, Fenerty V, Woods L, Grimmer C, Eccles DM, Foster C. Patient decision support resources inform decisions about cancer susceptibility genetic testing and risk management: a systematic review of patient impact and experience. *Front Health Serv*. 2023 May 31;3:1092816. doi: 10.3389/frhs.2023.1092816. PMID: 37395995; PMCID: PMC10311450
38. McAlister FA, Laupacis A, Armstrong PW. Finding the right balance between precision medicine and personalized care. *CMAJ*. 2017 Aug 21;189(33):E1065-E1068
39. Palsson, B. (2015). *Systems biology*. Cambridge university press
40. Trewavas A. A brief history of systems biology. "Every object that biology studies is a system of systems."
41. Francois Jacob (1974). *Plant Cell*. 2006 Oct;18(10):2420-30
42. Galas, David. "systems biology". *Encyclopedia Britannica*, 7 Dec. 2018, <https://www.britannica.com/science/systems-biology>. Accessed 13 February 2024
43. Iman Tavassoly, Joseph Goldfarb, Ravi Iyengar; *Systems biology primer: the basic methods and approaches*. *Essays Biochem* 26 October 2018; 62 (4): 487–500
44. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. *J Clin Oncol*. 2010 Jun 1;28(16):2777-83
45. Mambetsariev I, Fricke J, Gruber SB, Tan T, Babikian R, Kim P, Vishnubhotla P, Chen J, Kulkarni P, Salgia R. Clinical Network Systems Biology: Traversing the Cancer Multiverse. *J Clin Med*. 2023 Jul 7;12(13):4535. doi: 10.3390/jcm12134535. PMID: 37445570; PMCID: PMC10342467.
46. Turanli B, Karagoz K, Gulfidan G, Sinha R, Mardinoglu A, Arga KY. A Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision Medicine. *Curr Pharm Des*. 2018;24(32):3778-3790. doi: 10.2174/1381612824666181106095959. PMID: 30398107.
47. Fawaz A, Ferraresi A, Isidoro C. Systems Biology in Cancer Diagnosis Integrating Omics Technologies and Artificial Intelligence to Support Physician Decision Making. *J Pers Med*. 2023 Nov 10;13(11):1590. doi: 10.3390/jpm13111590. PMID: 38003905; PMCID: PMC10672164.
48. Najarian, K., Najarian, S., Gharibzadeh, S., & Eichelberger, C. N. (2009). *Systems biology and bioinformatics: a computational approach*. CRC Press
49. Palsson, B. (2015). *Systems biology*. Cambridge university press
50. Klipp, E., Herwig, R., Kowald, A., Wierling, C., & Lehrach, H. (2005). *Systems biology in practice: concepts, implementation and application*
51. John Wiley & Sons; Chen R, Snyder M. *Systems biology: personalized medicine for the future?* *Curr Opin Pharmacol*. 2012 Oct;12(5):623-8

52. Rees L, Weil A. Integrated medicine. *BMJ*. 2001 Jan 20;322(7279):119-20
53. <https://www.who.int/teams/integrated-health-services/traditional-complementary-and-integrative-medicine>; Integrative Medicine (Editors: David P. Rakel, Vincent Minichiello), 5th Edition – Elsevier, August 12, 2022
54. Debleena Guin, Sarita Thakran, Pooja Singh, S. Ramachandran, Yasha Hasija, Ritushree Kukreti, Chapter 1 - Translational biotechnology: A transition from basic biology to evidence-based research, Editor(s): Yasha Hasija, Translational Biotechnology, Academic Press, 2021, Pages 3-24
55. Lindahl, Sten and Marincola, Francesco. "translational medicine". *Encyclopedia Britannica*, 5 May. 2023, <https://www.britannica.com/science/translational-medicine>. Accessed 13 February 2024
56. Padilla-Cabello J, Santisteban-Espejo A, Heradio R, Cobo MJ, Martin-Piedra MA, Moral-Munoz JA. Methods for identifying biomedical translation: a systematic review. *Am J Transl Res*. 2022 Apr 15;14(4):2697-2708
57. Ahmed, Z. Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis. *Hum Genomics* 14, 35 (2020)
58. Tebani A, Afonso C, Marret S, Bekri S. Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations. *Int J Mol Sci*. 2016 Sep 14;17(9)
59. Kun-Hsing Yu, Michael Snyder, Omics Profiling in Precision Oncology, Molecular & Cellular Proteomics, Volume 15, Issue 8, 2016, Pages 2525-2536
60. M. Afzal, S. M. Riazul Islam, M. Hussain and S. Lee, "Precision Medicine Informatics: Principles, Prospects, and Challenges," in *IEEE Access*, vol. 8, pp. 13593-13612, 2020
61. Ying Yu, Yunjin Wang, Zhaojie Xia, Xiangyu Zhang, Kailiang Jin, Jingcheng Yang, Luyao Ren, Zheng Zhou, Dong Yu, Tao Qing, Chengdong Zhang, Li Jin, Yuanting Zheng, Li Guo, Leming Shi, PreMedKB: an integrated precision medicine knowledgebase for interpreting relationships between diseases, genes, variants and drugs, *Nucleic Acids Research*, Volume 47, Issue D1, 08 January 2019, Pages D1090–D1101
62. Moscatelli, M., Manconi, A., Pessina, M. et al. An infrastructure for precision medicine through analysis of big data. *BMC Bioinformatics* 19 (Suppl 10), 351 (2018)
63. Bjerrum A, Lassen U. Putting data to work for precision medicine. *Cell Rep Med*. 2023 Jul 18;4(7):101090
64. Simoes E. Health information technology advances health care delivery and enhances research. *Mo Med*. 2015 Jan-Feb;112(1):37-40
65. The Global Health Informatics landscape and JAMIA. Fraser HSF, Zahiri K, Kim N, Kim C, Craig S. *J Am Med Inform Assoc*. 2023 Mar 16;30(4):775-780
66. Aneja S, Avesta A, Xu H, Machado LO. Clinical Informatics Approaches to Facilitate Cancer Data Sharing. *Yearb Med Inform*. 2023 Aug;32(1):104-110. doi: 10.1055/s-0043-1768721. Epub 2023 Jul 6. PMID: 37414028; PMCID: PMC10751108
67. Pristner M, Warth B. Drug-Exposome Interactions: The Next Frontier in Precision Medicine. *Trends Pharmacol Sci*. 2020 Dec;41(12):994-1005; Manuel Pristner, Benedikt Warth, Drug-Exposome Interactions: The Next Frontier in Precision Medicine, Trends in Pharmacological Sciences, Volume 41, Issue 12, 2020, 994-1005; Baccarelli, A., Dolinoy, D.C. & Walker, C.L. A precision environmental health approach to prevention of human disease. *Nat Commun* 14, 2449 (2023).
68. van Harten AM, Brakenhoff RH. Targeted Treatment of Head and Neck (Pre)Cancer: Pre-clinical Target Identification and Development of Novel Therapeutic Applications. *Cancers (Basel)*. 2021 Jun 3;13(11):2774. doi: 10.3390/cancers13112774. PMID: 34204886; PMCID: PMC8199752.
69. Röcken C. Predictive biomarkers in gastric cancer. *J Cancer Res Clin Oncol*. 2023 Jan;149(1):467-481. doi: 10.1007/s00432-022-04408-0. Epub 2022 Oct 19. PMID: 36260159; PMCID: PMC9889517.
70. Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: A broad overview. *Crit Rev Oncol Hematol*. 2020 Nov;155:103109. doi: 10.1016/j.critrevonc.2020.103109. Epub 2020 Sep 25. PMID: 33049662.
71. Wallington-Beddoe CT, Mynott RL. Prognostic and predictive biomarker developments in multiple myeloma. *J Hematol Oncol*. 2021 Sep 23;14(1):151. doi: 10.1186/s13045-021-01162-7. PMID: 34556161; PMCID: PMC8461914.
72. Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. *Clin Exp Med*. 2023 Feb;23(1):1-16. doi: 10.1007/s10238-021-00781-1. Epub 2022 Jan 15. PMID: 35031885.
73. Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, Fang X, Zhang X. Exosomes as a new frontier of cancer liquid biopsy. *Mol Cancer*. 2022 Feb 18;21(1):56. doi: 10.1186/s12943-022-01509-9. PMID: 35180868; PMCID: PMC8855550.
74. Zhang, F., Chen, J.Y. Discovery of pathway biomarkers from coupled proteomics and systems biology methods. *BMC Genomics* 11 (Suppl 2), S12 (2010)
75. Chen H, Zhu Z, Zhu Y, Wang J, Mei Y, Cheng Y. Pathway mapping and development of disease-specific biomarkers: protein-based network biomarkers. *J Cell Mol Med*. 2015 Feb;19(2):297-314
76. Sheng M, Xie X, Wang J, Gu W. A Pathway-Based Strategy to Identify Biomarkers for Lung Cancer Diagnosis and Prognosis. *Evolutionary Bioinformatics*. 2019;15
77. Ben-Hamo, R., Jacob Berger, A., Gavert, N. et al. Predicting and affecting response to cancer therapy based on pathway-level biomarkers. *Nat Commun* 11, 3296 (2020)
78. Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. *Comput Struct Biotechnol J*. 2016 Jun 1;14:211-22
79. Purkayastha K, Dhar R, Pethusamy K, Srivastava T, Shankar A, Rath GK, Karmakar S. <https://www.>

- docplexus.com/posts/cancer-biomarkers-and-their-roles; The issues and challenges with cancer biomarkers. *Cancer Res Ther*. 2023 Apr;19(Supplement):S20-S35
80. Wang Z, Li R, Yang G, Wang Y. J Drug Target. 2024 Dec;32(1):33-44. Cancer stem cell bi-omarkers and related signalling pathways
 81. Chakraborty A, Patton DJ, Smith BF, Agarwal P. miRNAs: Potential as Biomarkers and Therapeutic Targets for Cancer. *Genes (Basel)*. 2023 Jun 29;14(7):1375
 82. Sheng W, Zhang C, Mohiuddin TM, Al-Rawe M, Zeppernick F, Falcone FH, Meinhold-Heerlein I, Hussain AF. Multiplex Immunofluorescence: A Powerful Tool in Cancer Immunotherapy. *Int J Mol Sci*. 2023 Feb 4;24(4):3086. doi: 10.3390/ijms24043086. PMID: 36834500; PMCID: PMC9959383.
 83. Tan WCC, Nerurkar SN, Cai HY, Ng HHM, Wu D, Wee YTF, Lim JCT, Yeong J, Lim TKH. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. *Cancer Commun (Lond)*. 2020 Apr;40(4):135-153. doi: 10.1002/cac2.12023. Epub 2020 Apr 17. PMID: 32301585; PMCID: PMC7170662.
 84. Harms PW, Frankel TL, Moutafi M, Rao A, Rimm DL, Taube JM, Thomas D, Chan MP, Pantanowitz L. Multiplex Immunohistochemistry and Immunofluorescence: A Practical Up-date for Pathologists. *Mod Pathol*. 2023 Jul;36(7):100197. doi: 10.1016/j.modpat.2023.100197. Epub 2023 Apr 25. PMID: 37105494.
 85. Lewis SM, Asselin-Labat ML, Nguyen Q, Berthelet J, Tan X, Wimmer VC, Merino D, Rogers KL, Naik SH. Spatial omics and multiplexed imaging to explore cancer biology. *Nat Methods*. 2021 Sep;18(9):997-1012. doi: 10.1038/s41592-021-01203-6. Epub 2021 Aug 2. PMID: 34341583.
 86. Van Gool A, Corrales F, Čolović M, Krstić D, Oliver-Martos B, Martínez-Cáceres E, Jakasa I, Gajski G, Brun V, Kyriacou K, Burzynska-Pedziwiatr I, Wozniak LA, Nierkens S, Pascual García C, Katrlík J, Bojic-Trbojevic Z, Vacek J, Llorente A, Antohe F, Suica V, Suarez G, t'Kindt R, Martin P, Penque D, Martins IL, Bodoki E, Iacob BC, Aydinoglu E, Timur S, Allinson J, Sutton C, Luider T, Wittfooth S, Sammar M. Analytical techniques for multiplex analysis of protein biomarkers. *Expert Rev Proteomics*. 2020 Apr;17(4):257-273. doi: 10.1080/14789450.2020.1763174. Epub 2020 May 19. PMID: 32427033.
 87. Hickey JW, Neumann EK, Radtke AJ, Camarillo JM, Beuschel RT, Albanese A, McDonough E, Hatler J, Wiblin AE, Fisher J, Croteau J, Small EC, Sood A, Caprioli RM, Angelo RM, Nolan GP, Chung K, Hewitt SM, Germain RN, Spraggins JM, Lundberg E, Snyder MP, Kelleher NL, Saka SK. Spatial mapping of protein composition and tissue organization: a primer for multiplexed antibody-based imaging. *Nat Methods*. 2022 Mar;19(3):284-295. doi: 10.1038/s41592-021-01316-y. Epub 2021 Nov 22. PMID: 34811556; PMCID: PMC9264278.
 88. Normanno N, Apostolidis K, de Lorenzo F, Beer PA, Henderson R, Sullivan R, Biankin AV, Horgan D, Lawler M. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. *Semin Cancer Biol*. 2022 Sep;84:293-301
 89. Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J, Maas J, Martinez A, Moch H, Nielsen S, Pilz T, Rouleau E, Patton S, Williams V. Access and quality of bi-omarker testing for precision oncology in Europe. *Eur J Cancer*. 2022 Nov;176:70-77
 90. Mishra, A.; Verma, M. Cancer Biomarkers: Are We Ready for the Prime Time? *Cancers* 2010, 2, 190-208
 91. Rao Bommi, J.; Kummari, S.; Lakavath, K.; Sukumaran, R.A.; Panicker, L.R.; Marty, J.L.; Yugender Goud, K. Recent Trends in Biosensing and Diagnostic Methods for Novel Cancer Biomarkers. *Biosensors* 2023, 13, 398
 92. Sarhadi VK, Armengol G. Molecular Biomarkers in Cancer. *Biomolecules*. 2022 Jul 23;12(8):1021; GARCÍA-CLOSAS, MONTSERRAT, and others, 'Application of Bi-omarkers in Cancer Epidemiology', in David Schottenfeld, and Joseph F. Fraumeni (eds), *Cancer Epidemiology and Prevention*, 3rd edn (New York, 2006; online edn, Oxford Academic, 1 Sept. 2009)
 93. Liu, D. Cancer biomarkers for targeted therapy. *Biomark Res* 7, 25 (2019)
 94. Shinozuka T, Kanda M, Kadera Y. Site-specific protein biomarkers in gastric cancer: a comprehensive review of novel biomarkers and clinical applications. *Expert Rev Mol Diagn*. 2023 Jul-Dec;23(8):701-712. doi: 10.1080/14737159.2023.2232298. Epub 2023 Jul 4. PMID: 37395000.
 95. Matsuoka T, Yashiro M. Novel biomarkers for early detection of gastric cancer. *World J Gastroenterol*. 2023 May 7;29(17):2515-2533. doi: 10.3748/wjg.v29.i17.2515. PMID: 37213407; PMCID: PMC10198055.
 96. Scholl S, Roufai DB, Chérif LL, Kamal M. RAIDS atlas of significant genetic and protein biomarkers in cervical cancer. *J Gynecol Oncol*. 2023 Sep;34(5):e74. doi: 10.3802/jgo.2023.34.e74. PMID: 37668079; PMCID: PMC10482580.
 97. Das S, Dey MK, Devireddy R, Gartia MR. Biomarkers in Cancer Detection, Diagnosis, and Prognosis. *Sensors (Basel)*. 2023 Dec 20;24(1):37. doi: 10.3390/s24010037. PMID: 38202898; PMCID: PMC10780704.
 98. Pabst L, Lopes S, Bertrand B, Creusot Q, Kotovskaya M, Pencreach E, Beau-Faller M, Mas-caux C. Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. *Int J Mol Sci*. 2023 Apr 20;24(8):7577. doi: 10.3390/ijms24087577. PMID: 37108738; PMCID: PMC10145126.
 99. Umapathy VR, Natarajan PM, Swamikannu B. Review Insights on Salivary Proteomics Bi-omarkers in Oral Cancer Detection and Diagnosis. *Molecules*. 2023 Jul 7;28(13):5283. doi: 10.3390/molecules28135283. PMID: 37446943; PMCID: PMC10343386.
 100. Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: Making precision medicine possible. *CA Cancer J Clin*. 2023 May-Jun;73(3):255-274. doi: 10.3322/caac.21768. Epub 2023 Jan 9. PMID: 36622841.
 101. van Renterghem AWJ, van de Haar J, Voest EE. Functional precision oncology using patient-derived

- assays: bridging genotype and phenotype. *Nat Rev Clin Oncol*. 2023 May;20(5):305-317. doi: 10.1038/s41571-023-00745-2. Epub 2023 Mar 13. PMID: 36914745.
102. Pomykala KL, Hadaschik BA, Sartor O, Gillissen S, Sweeney CJ, Maughan T, Hofman MS, Herrmann K. Next generation radiotheranostics promoting precision medicine. *Ann Oncol*. 2023 Jun;34(6):507-519. doi: 10.1016/j.annonc.2023.03.001. Epub 2023 Mar 15. PMID: 36924989.
 103. Lin X, Zong C, Zhang Z, Fang W, Xu P. Progresses in biomarkers for cancer immunothera-py. *MedComm* (2020). 2023 Oct 3;4(5):e387. doi: 10.1002/mco2.387. PMID: 37799808; PMCID: PMC10547938.
 104. Zhao Z, Li T, Yuan Y, Zhu Y. What is new in cancer-associated fibroblast biomarkers? *Cell Commun Signal*. 2023 May 4;21(1):96. doi: 10.1186/s12964-023-01125-0. PMID: 37143134; PMCID: PMC10158035.
 105. Saoudi González N, Salvà F, Ros J, Baraibar I, Rodríguez-Castells M, García A, Alcaráz A, Vega S, Bueno S, Tabernero J, Elez E. Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications. *Cancers (Basel)*. 2023 Aug 8;15(16):4020. doi: 10.3390/cancers15164020. PMID: 37627048; PMCID: PMC10452468.
 106. Lim YX, Mierzwa ML, Sartor MA, D'Silva NJ. Clinical, morphologic and molecular hetero-geneity of HPV-associated oropharyngeal cancer. *Oncogene*. 2023 Sep;42(40):2939-2955. doi: 10.1038/s41388-023-02819-y. Epub 2023 Sep 4. PMID: 37666939; PMCID: PMC10541327.
 107. Chen W, Xu D, Liu Q, Wu Y, Wang Y, Yang J. Unraveling the heterogeneity of cholangio-carcinoma and identifying biomarkers and therapeutic strategies with single-cell sequencing technology. *Biomed Pharmacother*. 2023 Jun;162:114697. doi: 10.1016/j.biopha.2023.114697. Epub 2023 Apr 13. PMID: 37060660.
 108. Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, Bunn PA Jr, Renyi-Vamos F, Schelch K, Prosch H, Byers LA, Hirsch FR, Dome B. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. *CA Cancer J Clin*. 2023 Nov-Dec;73(6):620-652. doi: 10.3322/caac.21785. Epub 2023 Jun 17. PMID: 37329269.
 109. Li J, Li L, You P, Wei Y, Xu B. Towards artificial intelligence to multi-omics characteriza-tion of tumor heterogeneity in esophageal cancer. *Semin Cancer Biol*. 2023 Jun;91:35-49. doi: 10.1016/j.semcancer.2023.02.009. Epub 2023 Mar 1. PMID: 36868394.
 110. Yu X, Liu R, Gao W, Wang X, Zhang Y. Single-cell omics traces the heterogeneity of pros-tate cancer cells and the tumor microenvironment. *Cell Mol Biol Lett*. 2023 May 9;28(1):38. doi: 10.1186/s11658-023-00450-z. PMID: 37161356; PMCID: PMC10170780.
 111. Wen R, Zhou L, Peng Z, Fan H, Zhang T, Jia H, Gao X, Hao L, Lou Z, Cao F, Yu G, Zhang W. Single-cell sequencing technology in colorectal cancer: a new technology to disclose the tumor heterogeneity and target precise treatment. *Front Immunol*. 2023 May 15;14:1175343. doi: 10.3389/fimmu.2023.1175343. PMID: 37256123; PMCID: PMC10225552.
 112. Yang P, Yang W, Wei Z, Li Y, Yang Y, Wang J. Novel targets for gastric cancer: The tumor microenvironment (TME), N6-methyladenosine (m6A), pyroptosis, autophagy, ferroptosis and cuproptosis. *Biomed Pharmacother*. 2023 Jul;163:114883. doi: 10.1016/j.biopha.2023.114883. Epub 2023 May 15. PMID: 37196545.
 113. Xu X, Zhou N, Lan H, Yang F, Dong B, Zhang X. The Ferroptosis Molecular Subtype Re-reveals Characteristics of the Tumor Microenvironment, Immunotherapeutic Response, and Prognosis in Gastric Cancer. *Int J Mol Sci*. 2022 Aug 29;23(17):9767. doi: 10.3390/ijms23179767. PMID: 36077165; PMCID: PMC9456108.
 114. Yang R, Yu Y. Patient-derived organoids in translational oncology and drug screening. *Cancer Lett*. 2023 May 28;562:216180. doi: 10.1016/j.canlet.2023.216180. Epub 2023 Apr 13. PMID: 37061121.
 115. Gu Y, Fang Y, Wu X, Xu T, Hu T, Xu Y, Ma P, Wang Q, Shu Y. The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications. *Exp Hematol Oncol*. 2023 Jul 6;12(1):58. doi: 10.1186/s40164-023-00420-3. PMID: 37415251; PMCID: PMC10324244.
 116. Tian X, Wang T, Shen H, Wang S. Tumor microenvironment, histone modifications, and myeloid-derived suppressor cells. *Cytokine Growth Factor Rev*. 2023 Dec;74:108-121. doi: 10.1016/j.cytogfr.2023.08.002. Epub 2023 Aug 12. PMID: 37598011.
 117. Chen Y, Li H, Fan Y. Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy. *Cancer Treat Rev*. 2023 Nov;120:102606. doi: 10.1016/j.ctrv.2023.102606. Epub 2023 Aug 7. PMID: 37579532.
 118. Li W, Zhou Z, Zhou X, Khoo BL, Gunawan R, Chin YR, Zhang L, Yi C, Guan X, Yang M. 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Or-ganoids, and Tumor-on-a-Chip. *Adv Healthc Mater*. 2023 Jul;12(18):e2202609. doi: 10.1002/adhm.202202609. Epub 2023 Mar 29. PMID: 36917657.
 119. Zhang J, Liu S, Chen X, Xu X, Xu F. Non-immune cell components in tumor microenviron-ment influencing lung cancer Immunotherapy. *Biomed Pharmacother*. 2023 Oct;166:115336. doi: 10.1016/j.biopha.2023.115336. Epub 2023 Aug 15. PMID: 37591126.
 120. Dagogo-Jack, I., Shaw, A. Tumour heterogeneity and resistance to cancer therapies. *Nat Rev Clin Oncol* 15, 81–94 (2018)
 121. Cirkel GA, Gadellaa-van Hooijdonk CG, Koudijs MJ, Willems SM, Voest EE. Tumor heter-ogeneity and personalized cancer medicine: are we being outnumbered? *Future Oncol*. 2014 Feb;10(3):417-28
 122. Duoqiao Wu, Diane C. Wang, Yunfeng Cheng, Mengjia Qian, Miaomiao Zhang, Qi Shen, Xiangdong Wang, Roles

- of tumor heterogeneity in the development of drug resistance: A call for precision therapy, *Seminars in Cancer Biology*. Volume 42, 2017, Pages 13-19
123. Guofeng Ma, Xuecheng Yang, Ye Liang, Liping Wang, Dan Li, Yuanbin Chen, Zhijuan Liang, Yonghua Wang, Haitao Niu, Precision medicine and bladder cancer heterogeneity. *Bulletin du Cancer*, Volume 105, Issue 10, 2018, 925-931
 124. Tomasik B, Garbicz F, Braun M, Bieńkowski M, Jassem J. Heterogeneity in precision oncology. *Cambridge Prisms: Precision Medicine*. 2024;2:e2. doi:10.1017/pcm.2023.23
 125. Tomasik B, Garbicz F, Braun M, Bieńkowski M, Jassem J. Heterogeneity in precision oncology. *Cambridge Prisms: Precision Medicine*. 2024;2:e2
 126. Jialing Zhang, Stephan Stanislaw Späth, Sadie L Marjani, Wengeng Zhang, Xinghua Pan, Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment, *Precision Clinical Medicine*, Volume 1, Issue 1, June 2018, Pages 29–48
 127. Tomasik B, Garbicz F, Braun M, Bieńkowski M, Jassem J. Heterogeneity in precision oncology. *Cambridge Prisms: Precision Medicine*. 2024;2:e2
 128. Marina Danilenko, Steven C. Clifford, Edward C. Schwalbe, Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma, *Pharmacology & Therapeutics*, Volume 228, 2021, 107828
 129. Dagogo-Jack, I., Shaw, A. Tumour heterogeneity and resistance to cancer therapies. *Nat Rev Clin Oncol* 15, 81–94 (2018)
 130. Cirkel GA, Gadella-van Hooijdonk CG, Koudijs MJ, Willems SM, Voest EE. Tumor heterogeneity and personalized cancer medicine: are we being outnumbered? *Future Oncol*. 2014 Feb;10(3):417-28
 131. Ahmed, Z. Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis. *Hum Genomics* 14, 35 (2020)
 132. Yijun Liu, Fuhu Song, Zhi Li, Liang Chen, Ying Xu, Huiyan Sun, Yi Chang. A comprehensive tool for tumor precision medicine with pharmacogenomics data analysis. *Front. Pharmacol.*, 2023, Vol 14, 1-9
 133. Maggi N, Gazzarata R, Ruggiero C, Lombardo C, Giacomini M. Cancer precision medicine today: Towards omic information in healthcare systems. *Tumori Journal*. 2019;105(1):38-46
 134. Maggi N, Gazzarata R, Ruggiero C, Lombardo C, Giacomini M. Cancer precision medicine today: Towards omic information in healthcare systems. *Tumori Journal*. 2019;105(1):38-46
 135. Dilara Akhoundova, Mark A. Rubin, Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future. *Cancer Cell*, Volume 40, Issue 9, 2022, 920-938
 136. Tebani A, Afonso C, Marret S, Bekri S. Omics-Based Strategies in Precision Medicine: Towards a Paradigm Shift in Inborn Errors of Metabolism Investigations. *Int J Mol Sci*. 2016 Sep 14;17(9):1555
 137. Hayes, D.F. OMICS-based personalized oncology: if it is worth doing, it is worth doing well! *BMC Med* 11, 221 (2013)
 138. Su, M. Y. & Fisher, D. E. Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. *PLoS Med*. 13, 2016
 139. Kosorok, M. R. & Laber, E. B. Precision Medicine. *Annu. Rev. Stat. its Appl.* 6, 263–286 (2019)
 140. Salgado, R. et al. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. *Eur. J. Cancer* 114, 128–136 (2019)
 141. Halabi, S. & Niedzwiecki, D. Advancing Precision Oncology Through Biomarker-Driven Trials: Theory vs. Practice. *Chance* 32, 23 (2019)
 142. Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: Driving Personalized Medicine. *Pharmacol Rev*. 2023 Jul;75(4):789-814. doi: 10.1124/pharmrev.122.000810. Epub 2023 Mar 16. PMID: 36927888; PMCID: PMC10289244.
 143. Moore C, Lazarakis S, Stenta T, Alexander M, Nguyen RP, Elliott DA, Conyers R. A systematic review of knowledge, attitude and practice of pharmacogenomics in pediatric oncology patients. *Pharmacol Res Perspect*. 2023 Dec;11(6):e01150. doi: 10.1002/prp2.1150. PMID: 38013228; PMCID: PMC10682497.
 144. Lim CX, Bozkurt A, Chen ZY, Hird A, Wickens J, Lazarakis S, Hussain SY, Alexander M. Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review. *Clin Transl Sci*. 2023 Dec;16(12):2467-2482. doi: 10.1111/cts.13672. Epub 2023 Nov 22. PMID: 37991131; PMCID: PMC10719462.
 145. de Joode K, Heersche N, Basak EA, Bins S, van der Veldt AAM, van Schaik RHN, Mathijssen RHJ. Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors. *Cancer Treat Rev*. 2024 Jan;122:102662. doi: 10.1016/j.ctrv.2023.102662. Epub 2023 Nov 27. PMID: 38043396.
 146. Tremmel R, Pirmann S, Zhou Y, Lauschke VM. Translating pharmacogenomic sequencing data into drug response predictions-How to interpret variants of unknown significance. *Br J Clin Pharmacol*. 2023 Sep 27. doi: 10.1111/bcp.15915. Epub ahead of print. PMID: 37759374.
 147. Bonetti G, Madeo G, Michelini S, Ricci M, Cestari M, Michelini S, Gadler M, Benedetti S, Guerri G, Cristofoli F, Generali D, Donofrio CA, Cominetti M, Fioravanti A, Riccio L, Benini A, Fulcheri E, Stuppia L, Gatta V, Cecchin S, Marceddu G, Bertelli M. Omics sciences and precision medicine in breast and ovarian cancer. *Clin Ter*. 2023 Nov-Dec;174(Suppl 2(6)):104-118. doi: 10.7417/CT.2023.2477. PMID: 37994754.
 148. Maciejko L, Smalley M & Goldman A. Cancer immunotherapy and personalized medicine: Emerging technologies and biomarker-based approaches. *J. Mol. Biomark. Diagn* 8, (2017)

149. Lee CH & Yoon HJ Medical big data: Promise and challenges. *Kidney Res. Clin. Pract* 36, 3–11 (2017)
150. Babu E, Sen S. Explore & actuate: the future of personalized medicine in oncology through emerging technologies. *Curr Opin Oncol.* 2024 Mar 1;36(2):93-101. doi: 10.1097/CCO.0000000000001016. Epub 2024 Jan 19. PMID: 38441149
151. Pfohl U, Pflaume A, Regenbrecht M, Finkler S, Graf Adelman Q, Reinhard C, Regenbrecht CRA, Wedeken L. Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed. *Cells.* 2021 Apr 17;10(4):928. doi: 10.3390/cells10040928. PMID: 33920536; PMCID: PMC8072767.
152. Pfohl U, Pflaume A, Regenbrecht M, Finkler S, Graf Adelman Q, Reinhard C, Regenbrecht CRA, Wedeken L. Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed. *Cells.* 2021 Apr 17;10(4):928. doi: 10.3390/cells10040928. PMID: 33920536; PMCID: PMC8072767.
153. Aguiar PN, Matsas S, Dienstmann R, Ferreira CG. Challenges and opportunities in building a health economic framework for personalized medicine in oncology. *Per Med.* 2023 Sep;20(5):453-460. doi: 10.2217/pme-2022-0008. Epub 2023 Aug 21. PMID: 37602420.
154. Pandiella A, Calvo E, Moreno V, Amir E, Templeton A, Ocana A. Considerations for the clinical development of immuno-oncology agents in cancer. *Front Immunol.* 2023 Aug 11;14:1229575. doi: 10.3389/fimmu.2023.1229575. PMID: 37638048; PMCID: PMC10451075.
155. De Pauw T, De Mey L, Debacker JM, Raes G, Van Ginderachter JA, DeGroof TWM, Devoogdt N. Current status and future expectations of nanobodies in oncology trials. *Expert Opin Investig Drugs.* 2023 Jul-Dec;32(8):705-721. doi: 10.1080/13543784.2023.2249814. Epub 2023 Aug 28. PMID: 37638538.
156. Parkinson JF, Ospina PA, Round J, McNeely ML, Jones CA. Generic Health Utility Measures in Exercise Oncology: A Scoping Review and Future Directions. *Curr Oncol.* 2023 Sep 28;30(10):8888-8901. doi: 10.3390/currenol30100642. PMID: 37887542; PMCID: PMC10605555
157. Fox, E. J. & Loeb, L. A. Cancer: One cell at a time. *Nature* 512, 143–144 doi:10.1038/nature13650. Macmillan Publishers
158. Ravneet Chhabra. Molecular and modular intricacies of precision oncology. *Front. Immunol.*, 2024, Sec. Cancer Immunity and Immunotherapy, Vol 15, PP 1-10 <https://doi.org/10.3389/fimmu.2024.1476494>
159. Cecchin E, Stocco G. Pharmacogenomics and personalized medicine. *Genes (Basel).* (2020) 11:679. doi: 10.3390/genes11060679
160. PA T, SS M, Jose A, Chandran L, Zachariah SM. Pharmacogenomics: the right drug to the right person. *J Clin Med Res.* (2009) 1:191–4. doi: 10.4021/jocmr2009.08.1255
161. Passaro A, Al Bakir M, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. *Cell.* 2024 Mar 28;187(7):1617-1635. doi: 10.1016/j.cell.2024.02.041. PMID: 38552610; PMCID: PMC7616034
162. Dubey AK, Kaur I, Madaan R, Raheja S, Bala R, Garg M, Kumar S, Lather V, Mittal V, Pandita D, Gundamaraju R, Singla RK, Sharma R. Unlocking the potential of oncology bi-omarkers: advancements in clinical theranostics. *Drug Metab Pers Ther.* 2024 Mar 12;39(1):5-20. doi: 10.1515/dmpt-2023-0056. PMID: 38469723
163. Giraldo NA, Peske JD, Sautès-Fridman C, Fridman WH. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. *Virchows Arch.* 2019 Apr;474(4):463-474. doi: 10.1007/s00428-018-02517-1. Epub 2019 Jan 10. PMID: 30631935
164. Dregely I, Prezzi D, Kelly-Morland C, Roccia E, Neji R, Goh V. Imaging biomarkers in on-cology: Basics and application to MRI. *J Magn Reson Imaging.* 2018 Jul;48(1):13-26. doi: 10.1002/jmri.26058. PMID: 29969192; PMCID: PMC6587121
165. Mechahougui H, Gutmans J, Colarusso G, Gouasmi R, Friedlaender A. Advances in Personalized Oncology. *Cancers (Basel).* 2024 Aug 16;16(16):2862. doi: 10.3390/cancers16162862. PMID: 39199633; PMCID: PMC11352922
166. Gazola AA, Lautert-Dutra W, Archangelo LF, Reis RBD, Squire JA. Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment. *Mol Cyto-genet.* 2024 Nov 14;17(1):28. doi: 10.1186/s13039-024-00698-w. PMID: 39543667; PMCID: PMC11566986
167. Riedl JM, Moik F, Esterl T, Kostmann SM, Gerger A, Jost PJ. Molecular diagnostics tailoring personalized cancer therapy - an oncologist's view. *Virchows Arch.* 2024 Feb;484(2):169-179. doi: 10.1007/s00428-023-03702-7. Epub 2023 Nov 20. PMID: 37982847; PMCID: PMC10948510
168. Lörsch AM, Jung J, Lange S, Pfarr N, Mogler C, Illert AL. Personalisierte Medizin in der Onkologie [Personalized medicine in oncology]. *Pathologie (Heidelb).* 2024 May;45(3):180-189. German. doi: 10.1007/s00292-024-01315-8. Epub 2024 Apr 3. PMID: 38568256
169. Cheng C, Fan B, Yang Y, Wang P, Wu M, Xia H, Syed BM, Wu H, Liu Q. Construction of an adverse outcome pathway framework for arsenic-induced lung cancer using a network-based approach. *Ecotoxicol Environ Saf.* 2024 Sep 15;283:116809. doi: 10.1016/j.ecoenv.2024.116809. Epub 2024 Jul 30. PMID: 39083875
170. Agamah FE, Bayjanov JR, Niehues A, Njoku KF, Skelton M, Mazandu GK, Ederveen THA, Mulder N, Chimusa ER, 't Hoen PAC. Computational approaches for network-based integrative multi-omics analysis. *Front Mol Biosci.* 2022 Nov 14;9:967205. doi: 10.3389/fmolb.2022.967205. PMID: 36452456; PMCID: PMC9703081
171. Qi X, Chen X, Zhao Y, Chen J, Niu B, Shen B. Prognostic Roles of ceRNA Network-Based Signatures in Gastrointestinal Cancers. *Front Oncol.* 2022 Jul 18;12:921194. doi: 10.3389/fonc.2022.921194. PMID:

- 35924172; PMID: PMC9339642
172. Park H, Miyano S. Computational Tactics for Precision Cancer Network Biology. *Int J Mol Sci*. 2022 Nov 19;23(22):14398. doi: 10.3390/ijms232214398. PMID: 36430875; PMID: PMC9695754
 173. Su K, Wang N, Shao Q, Liu H, Zhao B, Ma S. The role of a ceRNA regulatory network based on lncRNA MALAT1 site in cancer progression. *Biomed Pharmacother*. 2021 May;137:111389. doi: 10.1016/j.biopha.2021.111389. Epub 2021 Feb 15. PMID: 33601150
 174. Qi X, Lin Y, Chen J, Shen B. Decoding competing endogenous RNA networks for cancer bi-omarker discovery. *Brief Bioinform*. 2020 Mar 23;21(2):441-457. doi: 10.1093/bib/bbz006. PMID: 30715152
 175. Kyrochristos ID, Ziogas DE, Roukos DH. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. *Med Res Rev*. 2019 May;39(3):1205-1227. doi: 10.1002/med.21549. Epub 2018 Nov 11. PMID: 30417574
 176. D. Dhawan, Chapter 2 - Clinical Next-Generation Sequencing: Enabling Precision Medicine, Editor(s): Mukesh Verma, Debmalya Barh, Progress and Challenges in Precision Medicine, Academic Press, 2017, Pages 35-54
 177. Bashdar Mahmud Hussien, Sara Tharwat Abdullah, Abbas Salihi, Dana Khdr Sabir, Karzan R. Sidiq, Mohammed Fatih Rasul, Hazha Jamal Hidayat, Soudeh Ghafouri-Fard, Mohammad Taheri, Elena Jamali, The emerging roles of NGS in clinical oncology and personalized medicine, *Pathology - Research and Practice*, Volume 230, 2022, 153760)
 178. Wit, S., Dalum, G., Lenferink, A. et al. The detection of EpCAM+ and EpCAM- circulating tumor cells. *Sci Rep* 5, 12270 (2015). <https://doi.org/10.1038/srep12270>
 179. Fiori ME, Villanova L, De Maria R. Cancer stem cells: at the forefront of personalized medicine and immunotherapy. *Curr Opin Pharmacol*. 2017 Aug;35:1-11. doi: 10.1016/j.coph.2017.04.006. Epub 2017 May 18. PMID: 28527911
 180. Talukdar S, Emdad L, Das SK, Sarkar D, Fisher PB. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells. *Adv Cancer Res*. 2016;131:159-91. doi: 10.1016/bs.acr.2016.04.003. Epub 2016 Jun 3. PMID: 27451127
 181. Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, Zhai Z, Tanzhu G, Yang J, Zhou R. Can-cer stem cells: advances in knowledge and implications for cancer therapy. *Signal Transduct Target Ther*. 2024 Jul 5;9(1):170. doi: 10.1038/s41392-024-01851-y. PMID: 38965243; PMID: PMC11224386
 182. Akoya Biosciences, 2021. <https://www.akoyabio.com/webinar/know-thy-neighborhood-spatial-phenotyping-of-cells-at-the-neighborhood-level>
 183. Islam F, Gopalan V, Smith RA, Lam AK. Translational potential of cancer stem cells: A re-view of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment. *Exp Cell Res*. 2015 Jul 1;335(1):135-47. doi: 10.1016/j.yexcr.2015.04.018. Epub 2015 May 9. PMID: 25967525
 184. Islam F, Gopalan V, Smith RA, Lam AK. Translational potential of cancer stem cells: A re-view of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment. *Exp Cell Res*. 2015 Jul 1;335(1):135-47. doi: 10.1016/j.yexcr.2015.04.018. Epub 2015 May 9. PMID: 25967525
 185. Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the poten-tial. *Semin Oncol*. 2015 Apr;42 Suppl 1:S3-17. doi: 10.1053/j.seminoncol.2015.01.001. Epub 2015 Jan 21. PMID: 25839664
 186. Cheng L, Alexander R, Zhang S, Pan CX, MacLennan GT, Lopez-Beltran A, Montironi R. The clinical and therapeutic implications of cancer stem cell biology. *Expert Rev Anticancer Ther*. 2011 Jul;11(7):1131-43. doi: 10.1586/era.11.82. PMID: 21806335
 187. Bamodu OA, Chung CC, Pisanic TR 2nd, Wu ATH. The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies. *Front Oncol*. 2024 May 10;14:1404628. doi: 10.3389/fonc.2024.1404628. PMID: 38800385; PMID: PMC11116576
 188. Anders Edsjö, Louise Holmquist, Birgit Georger, Frédérique Nowak, Georgy Gomon, Cath-erine Alix-Panabières, Johan Staaf, Carolin Ploeger, Ulrik Lassen, Christophe Le Tourneau, Janne Lehtiö, Patrick A. Ott, Andreas von Deimling, Stefan Fröhling, Emile Voest, Frederick Klauschen, Rodrigo Dienstmann, Aisha Alshibany, Lillian L. Siu, Albrecht Stenzinger. Pre-cision cancer medicine: Concepts, current practice, and future developments. *J Intern Med*. 2023;294:455-481
 189. Su, M.; Zhang, Z.; Zhou, L.; Han, C.; Huang, C.; Nice, E.C. Proteomics, Personalized Medi-cine and Cancer. *Cancers* 2021, 13, 2512. <https://doi.org/10.3390/cancers13112512> (modi-fied)
 190. Smith A, Loshak H. Pharmacogenomic Testing for Medication Selection: A Rapid Qualita-tive Review [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Aug 24. PMID: 33320483
 191. Shahani SA, Marcotte EL. Landscape of germline cancer predisposition mutations testing and management in pediatrics: Implications for research and clinical care. *Front Pediatr*. 2022 Sep 26;10:1011873. doi: 10.3389/fped.2022.1011873. PMID: 36225340; PMID: PMC9548803
 192. Stevenson JM, Smith DM, Tuteja S, Patel JN; Pharmacogenomics Global Research Network (PGRN) Publications Committee. Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test. *Clin Pharmacol Ther*. 2025 May 5. doi: 10.1002/cpt.3704. Epub ahead of print. PMID: 40325943
 193. Li J, Tian J, Liu Y, Liu Z, Tong M. Personalized analysis of human cancer multi-omics for precision oncology. *Comput Struct Biotechnol J*. 2024 May 10;23:2049-2056. doi: 10.1016/j.csbj.2024.05.011. PMID: 38783900; PMID: PMC11112262
 194. Mechahougui H, Gutmans J, Colarusso G, Gouasmi

-
- R, Friedlaender A. *Advances in Personalized Oncology. Cancers (Basel)*. 2024 Aug 16;16(16):2862. doi: 10.3390/cancers16162862. PMID: 39199633; PMCID: PMC11352922
195. Dougherty SC, Flowers WL, Gaughan EM. Precision Oncology in Melanoma: Changing Practices. *J Nucl Med*. 2024 Dec 3;65(12):1838-1845. doi: 10.2967/jnumed.124.267781. PMID: 39542696; PMCID: PMC11619585
196. Montin D, Santilli V, Beni A, Costagliola G, Martire B, Mastrototaro MF, Ottaviano G, Rizzo C, Sgrulletti M, Miraglia Del Giudice M, Moschese V. Towards personalized vaccines. *Front Immunol*. 2024 Oct 3;15:1436108. doi: 10.3389/fimmu.2024.1436108. PMID: 39421749; PMCID: PMC11484009
197. Lawler M, Keeling P, Kholmanskikh O, Minnaard W, Moehlig-Zuttermeister H, Normanno N, Philip R, Popp C, Salgado R, Santiago-Walker AE, Trullas A, van Doorn-Khosrovani SBVW, Vart R, Vermeulen J, Vitaloni M, Verweij J. Empowering effective biomarker-driven precision oncology: A call to action. *Eur J Cancer*. 2024 Sep;209:114225. doi: 10.1016/j.ejca.2024.114225. Epub 2024 Jul 15. PMID: 39053288.
198. Adi-Wauran E, Krishnapillai S, Uleryk E, Saeedi S, Bombard Y. Patient-centred care in precision oncology: A systematic review. *Patient Educ Couns*. 2025 Jul;136:108753. doi: 10.1016/j.pec.2025.108753. Epub 2025 Mar 12. PMID: 40121935.

Copyright:

©2026 Sergey Suchkov, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.